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Abstract 
Background: Despite adequate glycemic control, the risks of perinatal complications 
and fetal macrosomia are increased in pregnancies with pregestational diabetes 
(PGDM). Maternal overweight, obesity and excess gestational weight gain add 
significantly to the risk of large for gestational age offspring in PGDM pregnancies. 
Umbilical perfusion of the fetal liver has a key role in regulating fetal growth. We 
hypothesized that PGDM alters umbilical venous distribution and fetal liver blood 
flow depending on maternal anthropometry and glycemic control. 
Aims: The aims were to study a population with PGDM to 1) Compare the 
longitudinal development of the venous liver flow with a low-risk population 2) 
Assess the relation between maternal HbA1C and fetal venous liver flow 3) Explore 
the influence of maternal body mass index (BMI) and weekly gestational weight gain 
(GWG) on the venous liver flow 4) Test if fetal flow was related to birthweight 
differently in PGDM compared with the reference population.  
Materials and methods: In a prospective longitudinal observational study, 49 
women with PGDM underwent monthly ultrasound examinations in gestational 
weeks 20 – 36. The time average maximum blood velocity was measured by Doppler 
in the umbilical vein (UV), ductus venosus (DV), left portal vein (LPV) and portal 
vein (PV). The inner vessel diameter was measured in UV, DV and PV, and the blood 
flow was calculated. Flow was normalized for estimated fetal weight.  
 
Mean and percentile curves were modelled by multilevel regression and compared 
with reference curves from a low-risk population (n=160). In addition, differences 
between mean fetal flow z -scores in the PGDM and low-risk populations were tested 
by independent sample t-test. HbA1C was measured in the first trimester and the 
relation to fetal venous flow was assessed by multilevel regression. 
 
Pre-pregnancy BMI and weekly GWG were calculated from self-reported pre-
pregnancy weight and maternal height, and the last maternal weight that was 
measured before delivery. ANOVA was used to test fetal flow differences between 
the BMI and GWG categories, and to test differences between birthweight in fetal 
flow categories. The impact of BMI and weekly GWG on the fetal flow variables was 
investigated by log-likelihood statistics. 
 
Results: Compared with the reference, UV flow, LPV velocity, umbilical venous 
liver flow and total venous liver flow were larger, and the DV flow was smaller in 
PGDM pregnancies. In the PGDM population birthweights were high and when 
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normalized for estimated fetal weight the UV and total venous liver flow were 
smaller than the reference values. The most prominent deviations from the reference 
curves were seen after 30 weeks of gestation and near term.  
 
DV shunting and PV fraction of total venous liver flow were negatively, and LPV 
velocity positively related to first trimester HbA1C.  
 
There was a graded positive association between UV flow, umbilical venous liver 
flow, total venous liver flow, LPV velocity and birthweight, and this effect was more 
pronounced in PGDM pregnancies than in the low-risk reference population.  BMI 
and GWG modified venous liver flow to a larger extent in PGDM pregnancies than in 
the reference population. Overweight women with PGDM had the highest umbilical 
venous liver flow, total venous liver flow and LPV velocity, while PV fraction was 
lower. Those with excessive GWG had the largest UV flow, umbilical venous liver 
flow and LPV velocity, and lower PV fraction, compared with the other GWG 
categories.  
 
Conclusion: This study provides new insight to the fetal development and the 
physiological mechanisms contributing to increased risks in PGDM pregnancies. UV 
flow to the liver was prioritized at the expense of DV shunting. Reduced DV shunting 
could increase neonatal risks by inhibiting fetal compensatory responses to hypoxia 
near term and during labour. 
 
Increased distribution of UV blood to the liver contributed to larger birthweight in 
PGDM pregnancies, and maternal glycemic control influences the distribution of fetal 
liver flow.  After 30 gestational weeks however, the blunted development of the 
umbilical venous liver flow caused an increasing mismatch between fetal growth and 
venous blood supply in the third trimester. The modification of fetal flow and 
birthweight by BMI and GWG was larger in PGDM pregnancies than in the reference 
population.  
 
Our study supports the concept that fetal liver perfusion is an important regulator of 
fetal growth.  We found this mechanism to be augmented in PGDM pregnancies.  
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What was already known What this study adds 
Paper I 
In low-risk pregnancies, umbilical venous (UV) 
and normalized UV flow increase during the 
second half of pregnancy with blunting near term. 
In fetal growth restriction (FGR) the UV flow is 
reduced depending on the degree of circulatory 
compromise. UV flow is higher in macrosomic 
fetuses of healthy women, also when normalized 
for fetal weight. 
In low-risk pregnancies, 20-30% of the UV flow 
is shunted through the ductus venosus (DV). Non-
diabetic macrosomic fetuses shunt less UV blood 
through the DV in late pregnancy. In FGR a 
higher proportion of the UV flow is shunted 
through the DV.  
 
In pregnancies with pregestational diabetes 
mellitus (PGDM) UV flow was larger than in 
low-risk pregnancies, but reduced when 
normalized for fetal weight. 
In pregnancies with PGDM, the DV flow, 
normalized DV flow and DV shunt fraction 
were lower, and this reduction was more 
pronounced near term. There was a negative 
relation between the degree of DV shunting, and 
maternal glycemic control in the first trimester 
(HbA1C).  
The difference in estimated flow between the 
reference and pregnancies with PGDM was 
caused by larger UV size, and lower DV flow 
velocity.  
Paper II 
The flow velocity in the left portal vein, portal 
vein flow and contribution to the total venous 
liver supply increases towards term in low-risk 
pregnancies. In macrosomic fetuses of healthy 
mothers, liver flow volumes are higher than the 
reference, but similar when the flow is normalised 
for fetal weight. In fetal growth restriction the 
total venous liver flow is reduced, also relative to 
fetal weight. 
Fetal liver volume is positively related to HbA1C 
in pregnancies with diabetes.  
 
In PGDM pregnancies, the fetal venous liver 
flow was larger than the reference before 30 
gestational weeks. After this time, when 
normalized for fetal weight, total venous liver 
flow was smaller. 
The left portal vein velocity as a measure of UV 
flow to the right liver lobe was positively related 
to maternal glycemic control in the first 
trimester, while the portal fraction of the total 
venous liver flow was negatively related to first 
trimester HbA1C, in PGDM pregnancies.  
Paper III 
In low-risk pregnancies, low maternal weight 
gain is associated with a preferential supply of 
UV blood to the left liver lobe.  
In PGDM maternal weight and weight gain is 
related to degree of overgrowth and macrosomia, 
even when the maternal glycemic control is good.  
 
 
The association between UV flow distribution 
and birthweight was more pronounced in PGDM 
pregnancies than in the low-risk population. 
In pregnancies with PGDM, body mass index 
and gestational weight gain modified fetal 
venous liver flow. Maternal overweight and 
excessive weight gain was associated with 
higher umbilical and total venous liver flows. 
Women with PGDM combined with overweight 
or excessive weight gain gave birth to neonates 
with the highest birthweights.  
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1.1 Diabetes in pregnancy 
1.1.1 History 
Descriptions of a condition causing “too great emptying of urine” appeared in Egypt 
around 1500 B.C and “sweet urine” was noted in India, but it was the Greek 
physician Aretaeus (probably 1
st
 century A.D) who first defined diabetes (Fig.1) (3).  
Until the discovery of insulin in 1921, by the Banting, Best and MacLeod 
collaboration, treatment was primitive and life expectancy short for people with 
diabetes mellitus (4, 5).  Consequently, pregnancies in women with diabetes were 
very rare, and according to the 1920 edition of Williams Textbook of Obstetrics, the 
prognosis was “ominous for mother and child”.  Indeed, women with diabetes were 
“giving birth astride of a grave” (6).  
 
Figure 1 Portrait of Aretaeus (Courtesy of the Bibliothèque Nationale de France), who 
authored On the Causes, Symptoms and Cure of Acute and Chronic Diseases (7). 
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1.1.2 Definitions and epidemiology 
The International Association of Diabetes in Pregnancy Study Group (IADPSG) and 
the World Health Organization (WHO) have reclassified hyperglycemia in pregnancy 
into three groups; diabetes diagnosed in pregnancy expected to continue postnatally 
(DIP), gestational diabetes (GDM) (8, 9) and pregestational diabetes (PGDM) 
diagnosed before pregnancy; type 1 or type 2 diabetes mellitus.  Other forms of 
diabetes will not be discussed in this thesis. 
In 2016 WHO estimated the global prevalence of diabetes to be 8.5%, an almost 
fourfold increase since 1980, reflecting the rise in risk factors such as overweight and 
obesity (10).  These factors also affect women of fertile age, but mainly because of 
variations in the diagnostic criteria for GDM and ethnic differences, reported 
prevalence of diabetes in pregnancy range widely, from 2 – 25% (11, 12).  According 
to the Medical Birth Registry of Norway, 5.8% of women had diabetes in pregnancy 
in 2016; 3.7/1000 type 1 diabetes mellitus (DM), 1.9/1000 type 2 DM and 51.5/1000 
GDM (13).  In 2017 the IADPSG recommendations for GDM were incorporated into 
Norwegian guidelines, and the prevalence of GDM is expected to reach 8 – 10% (14).  
Fortunately, the prognosis in PGDM pregnancies has improved greatly over the last 
century (5).  Still, the advances in medical therapy and routines for close clinical 
follow-up have not resulted in outcomes for women with PGDM approximating those 
of the background population (15).  The mothers have increased risks of preeclampsia 
and operative delivery (16), and in a Dutch nationwide study the combined perinatal 
morbidity in type 1 DM pregnancies was 80% (17).  Complications such as 
congenital anomalies, premature delivery, macrosomia, neonatal intensive care 
admission, neonatal hypoglycemia and perinatal death are more frequent in PGDM 
pregnancies (16-20). 
 16 
1.2 Maternal and fetal physiology 
1.2.1 The normal development 




 week of gestation, organs develop from 
three germ layers (organogenesis).  Diffusion is no longer sufficient for nutrition, and 
the complex formation of the cardiovascular system initiates.  
The fetal venous system 
Three major pairs of veins can be distinguished from gestational week 5; the vitelline, 
umbilical and cardinal veins.  The vitelline veins drain the yolk sac and form the 
hepatic sinusoids, and from this anastomotic network the portal vein (PV) develops.  
The umbilical veins drain the chorion and connect to the hepatic sinusoids, the right 
vein disappears, and the left umbilical vein (UV) then becomes the dominant vessel 
for blood flow from the placenta.  The cardinal veins develop to become the venous 
drainage of the embryo, including the formation of the proximal inferior vena cava 
(IVC) (21).  With increasing UV flow the ductus venosus (DV) forms, and by the 8
th
 
gestational week DV is a well-defined shunt between the UV and the IVC (Fig. 2) 
(22).  
The fetal liver 
From endodermal epithelium at the distal end of the foregut, the liver bud forms in 
gestational week 3.  Epithelial liver cords, the vitelline veins and the umbilical veins 
develop to become hepatic sinusoids, and the afferent and efferent venous network of 
the fetal liver is formed through complex vessel growth and asymmetric degeneration 
of vessels (23).  The afferent veins include the UV, PV and DV, and the efferent 
system is constituted of the hepatic veins (24).  
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Figure 2 After the 8th gestational week the ductus venosus forms a shunt between the 
umbilical vein and inferior vena cava. The vitelline veins form the superior mesenteric, 
splenic and portal veins. The left umbilical vein has become the dominant vein for flow from 
the placenta. Reprinted with permission from T. Kiserud; The ductus venosus in the human 
fetus (Univ. of Trondheim, 1994) 
Fetal blood 
Hematopoiesis occurs in the liver during fetal life (25).  Fetal erythrocytes are larger 
than adult erythrocytes, with a shorter life span, and the fetal hemoglobin 
concentration reaches 18 g/dL near term (26).  The feto-placental blood volume is 
approximately 125 mL/kg fetal weight or 10 – 12% of the body weight at term (27).  
The combined cardiac output per kilo fetal weight, approximately 400 ml/min/kg, is 
constant during pregnancy (28-30).  There is a high capacity for diffusion between 
the fetal compartments making blood volume compensation in response to events like 






Figure 3 The venous supply to the fetal liver. A cross section of the fetal abdomen, with 
black arrows indicating physiological blood flow directions in the fetal liver (grey). The left 
liver lobe is supplied entirely by well-oxygenated umbilical venous (UV) blood (red), then 
UV blood is shunted through the ductus venosus (DV). Typically, UV blood blends in with 
deoxygenated portal blood (PV) (blue) to feed the right liver lobe; UV, umbilical vein; DV, 
ductus venosus; LPV, Left portal vein; PV, portal vein; S, spine; V, stomach 
Venous anatomy and oxygenation 
Nutrient- and oxygen-rich blood from the placenta enters the fetus through the UV.  
Most of the UV blood is distributed to the fetal liver, first via UV branches to the left 
liver lobe (Fig. 3).  A fraction of the UV blood is directed to the heart through the 
DV.  The rest of the UV blood is distributed to the right liver lobe through the left 
portal vein (LPV) where it blends blood form the portal vein (PV) (Fig. 3 and 4) (32).   
The intraabdominal part of the UV, between the abdominal wall and the DV, is a 
relatively large fetal vein; the UV diameter grows from 2.5 to 6 mm during the last 
half of pregnancy (32).  The DV remains a slender, trumpet shaped structure, with 
diameter 1mm, rarely up to 2 mm, and length 15 mm in the third trimester (32, 33).  
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Mavrides et al. demonstrated no sphincter at the DV inlet, but described an elastin-
rich shelf structure and a narrow inlet, facilitating accelerated blood velocity through 
the DV (34).  Also, a single layer of longitudinally arranged smooth muscle cells 
along the entire length of the DV were present.  This allows active regulation of the 
vessel diameter, in response to stimuli (see below; Regulation of venous flow) (35). 
The LPV is the short venous section, about 1 cm, between the DV and the right portal 
vein (Fig. 3).  UV blood is normally directed to the right liver lobe through the LPV, 
but under certain conditions the LPV flow can reverse.  The LPV is therefore 
described as a watershed area; between the umbilical venous and the portal venous 
circulation (36).  Blood with low oxygen saturation (30%) from the spleen, stomach, 
pancreas and intestine is collected in the PV and transported to the right liver lobe 
(37).  The right liver lobe thus receives a mixture of blood with high and lower 
oxygen content, through the LPV and PV (Fig. 3) (38). 
Distinct pathways in the circulation enable the fetus to prioritize supply of blood to 
vital organs:  Highly oxygenated blood from the UV is distributed through the “via 
sinistra”; the DV, foramen ovale, left atrium, left ventricle and ascending aorta.  The 
anatomical and functional qualities of the DV, the IVC and the atrial septum, create a 
preferential flow of well-oxygenated blood to the left atrium (39, 40), mainly 
supplying the coronary arteries and the brain.  Through the “via dextra”, 
deoxygenated blood from the superior and inferior vena cava flow to the right atrium, 
right ventricle, pulmonary trunk, ductus arteriosus and descending aorta (23, 37).  
The highest oxygen saturation in the fetal circulation is in the UV and is reported to 
be 80%.  The lowest saturation is 30 – 35% in the IVC and PV (41).  The left liver 
lobe is thus perfused by highly oxygenated UV blood, from which the left liver of 
fetal lamb extracts only 10 – 15% of the available O2 (42).  Flow from the left and 
medial hepatic vein is therefore another source of oxygen, and this blood is 
preferentially streamed into the “via sinistra”, with some spillover to the right side of 
the atrial septum.  This reduces the difference in oxygen saturation in fetal lamb, 
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between the “via sinistra” (SaO2 55 – 60%), and the “via dextra” (SaO2 40 – 45%) 
(37, 43).  
Distribution of fetal venous flow 
In humans, the DV shunt fraction (proportion of UV blood shunted through the DV) 
is 30% in week 20 and decreases to 20 % from week 30 of pregnancy (32, 44).  
Consequently, 70 – 80% of the UV blood perfuses the liver, illustrating the high 
priority of this organ under physiological conditions (45).  
Similar to the UV and DV flows, LPV flow velocity steadily increases from 
gestational week 20, reaching a plateau in week 36 (36).  The PV flow also increases 
during the last half of pregnancy and the PV fraction (contribution of PV flow to total 
venous liver flow) rises from 14% at mid-gestation to 20% near term (45, 46).   
Regulation of venous flow 
Pressure, viscosity and vascular resistance influence the flow and distribution of UV 
blood.  The umbilico-caval pressure gradient, the difference in pressure between the 
UV and the IVC, drives the blood flow through the DV and the liver vasculature.  
Viscosity has a larger impact in the low velocity liver flow than in the high velocity 
DV flow, because low velocity gives higher viscous resistance.  Fluid dynamics thus 
attribute to increased DV shunting at low pressures and when hematocrit is high, like 
in situations of fetal hypoxia.  And contrary, with a higher umbilico-caval pressure 
gradient, relatively more UV blood perfuses the liver (47).  Respiratory movements 
influence the central venous pressures and thus the umbilico-caval pressure gradient.  
Fetal respiratory movements thereby partly regulate fetal hemodynamics (48), and 
flow measurements should therefore be performed during fetal quiescence. 
The existence of an anatomical DV sphincter has been controversial, but some degree 
of functional responsiveness and sensitivity to hormones is recognized (49); 
vasoconstriction occurs in response to α-adrenergic substances, and β-adrenergic 
stimulation induces vasodilation (50-52).  The DV dilates during hypoxia in fetal 
sheep (53), but in human growth restricted fetuses the effect of DV dilatation may be 
moderate (54-56).  Since also the hepatic vasculature is sensitive to neural and 
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hormonal signals, this is important in the regulation of venous flow (57, 58).  
Tchirikov et al. showed that the response to neurohormonal signals is more 
pronounced in the liver vasculature than in the DV (50).  Given the large cross 
sectional area of the liver vasculature, small changes in liver resistance may 
contribute substantially to changes in venous flow, including the DV shunting (23).  
 
Figure 4 Diagrammatic representation of the fetal circulation, showing flow of nutrient 
rich and highly oxygenated blood (red) from the placenta through the umbilical vein (UV). 
Ductus venosus (DV) bypasses the liver to supply the heart and brain with UV blood. The 
left liver lobe receives UV blood (red). The right liver lobe is mainly perfused with UV 
blood through the left portal vein (LPV) mixed with portal venous (PV) blood lower in 
oxygen-and nutrients (blue) (see also Fig. 3).  
Fetal liver, venous flow and growth 
The fetal liver has vital functions, such as hematopoiesis, nutrient metabolism, 
detoxification of venous blood, protein synthesis, fat storage and glucose 
homeostasis.  The development of the fetal liver parenchyma is influenced by the 
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distribution of UV blood; the left- and right liver lobes have different architectures 
and functionality (59).  It has been postulated that the pattern of UV blood 
distribution, to the brain and the liver, may have long-term consequences to the 
metabolism and body composition (60).   
The distribution of UV blood to the fetal liver is an important mechanism in the 
regulation of fetal growth (61, 62).  Experimentally increasing the UV blood flow to 
the liver, leads to increased cell proliferation, in the liver, heart, skeletal muscle and 
kidneys (63).  If the flow of UV blood to the liver is high, the liver nutrient supply is 
excessive.  A strong relation has been demonstrated between umbilical venous liver 
flow and infant fat mass at birth and at 4 years age (60, 64). 
In non-diabetic pregnancies with macrosomia, UV flow is increased, including when 
normalized for fetal weight (65).  Also, the total venous blood flow is augmented in 
macrosomia and a relatively higher proportion of UV blood perfuse the left liver lobe, 
while the PV fraction is decreased (62). 
1.2.2 Fetal hypoxemia and venous flow 
The fetal hemodynamic changes observed in pregnancies with placental compromise 
illustrate the physiological responsiveness in the fetal circulation.  Experiments on 
fetal sheep have shown that there is a considerable increase in DV shunting when the 
fetus is exposed to hypoxia (53, 66), prioritizing highly oxygenated blood to the heart 
and brain.  This has been confirmed in ultrasound studies of human pregnancies with 
severe growth restriction (54, 55).  Compromised UV flow has a graded effect on the 
DV shunting (35 - 57%) (54), and in extreme cases the LPV flow can be reversed 
(55).  When DV shunting is increased, the PV fraction is augmented.  In cases of 
critical placental compromise, the right liver lobe can be perfused by deoxygenated 
PV blood only (67).  Assessment of the fetal hemodynamics through Doppler 
velocimetry of the fetal circulation (umbilical artery, middle cerebral artery and DV) 
is commonly utilized in the diagnosis and surveillance of pregnancies with placental 
insufficiency (or/and anemia) (68-70).   
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1.2.3 Pregestational diabetes mellitus 
Early fetal development 
Through a series of experiments, Freinkel and Metzger developed the concept of 
“fuel mediated teratogenesis”. They postulated that increased levels of nutrients, most 
importantly glucose, can affect fetal development, with short- and possibly long term 
consequences (71).  Hyperglycemia during early embryogenesis may induce 
oxidative stress and through mechanisms partly unknown, cause congenital anomalies 
(72-74).  Pre-pregnancy care has therefore long been a part of routine in diabetes 
counselling, but several studies show no improvements in the risk of anomalies 
during the last two to three decades (15, 18, 75, 76).  The risk of congenital anomalies 
in a Norwegian PGDM population was 5.7% (OR 2.1) (1999 – 2004) (18), and a 
Danish study showed that 74% of congenital heart defects were attributable to PGDM 
(75).  
Fetal growth and macrosomia 
According to the Pedersen hypothesis, high maternal blood glucose results in fetal 
hyperglycemia, pancreatic cell overstimulation  and hyperinsulinemia, and this is a 
causal pathway to fetal overgrowth in diabetic pregnancies (77).  Macrosomia is an 
adverse outcome by itself, and is associated with events like stillbirth, fetal distress, 
operative delivery, shoulder dystocia and neonatal hypoglycemia (76, 78).  In Sweden 
the risk of macrosomia (at term birthweight >4500g) or large for gestational age 
(LGA) (birthweight >90
th
 gestational age specific percentile) was twelvefold in type 1 
DM pregnancies compared with a background population (16).  Of infants from 
women with type 1 diabetes, 32 – 57% were LGA (16, 20, 79), and Persson et al. 
reported that this incidence was increasing (16).  In type 1 DM populations with 
adequate HbA1C, nearly half of the infants were born LGA (79), with 3
rd
 trimester 
HbA1C and birthweight showing linear relations (80, 81).   
Gestation induces maternal peripheral insulin resistance and larger insulin 
fluctuations (82).  In pregnant women with PGDM, normally able to cope with their 
chronic disease, these metabolic changes make optimal glucose control difficult to 
accomplish (83, 84).  Although the use of continuous glucose monitors has shown 
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promising results in PGDM pregnancies, the prevalence of macrosomia and LGA in 
groups using such monitors was 31% and 53% respectively in two recent studies (84, 
85).   
The fetal liver 
The fetal liver development is affected by the levels of hormones and growth factors, 
such as insulin and insulin like growth factors (86, 87).  In diabetic rats, uncontrolled 
severe diabetes led to reduced fetal liver size and growth restriction (88).  Insulin 
treatment in diabetic pregnancies was associated with reduction of fetal liver insulin 
receptors, hyperinsulinemia and macrosomia (89).  Also in rats, studies have found 
decreased insulin sensitivity in peripheral tissues and livers of adult PGDM offspring, 
suggesting some long term consequences of PGDM for later health (90).  In pigs, 
diabetes induced fetal liver hyperplasia and increased glycogen reserves (91). 
Boito et al. assessed fetal liver volume by ultrasound in human pregnancies with 
PGDM, finding a strong correlation between liver size and maternal HbA1C, as well 
as a positive association between liver volume and fetal weight (92).  In human 
stillborn neonates of PGDM pregnancies, hepatic steatosis is prevalent and more 
severe than in stillborn of non-diabetic pregnancies (93). 
Maternal – and fetal circulation, and the placenta 
In pregnancies with diabetes, studies report contradictory results, and fetal circulatory 
adaptations typical to PGDM have not been identified (94, 95).  Maternal 
pregestational vasculopathy is related to abnormal uterine artery pulsatile index (PI) 
and adverse neonatal outcomes (96).  There is evidence that the risks of stillbirth and 
fetal distress are related to a state of chronic fetal acidemia and hypoxemia in diabetic 
pregnancies (97-101).  This could be due to reduced materno-placental oxygen supply 
and/or increased fetal oxygen demand.  Maternal vascular complications in mothers 
with diabetes can cause reduced arterial oxygen saturation (102), and in diabetic 
pregnancies reduced utero-placental blood flow has been reported (103). Doppler of 
the uterine arteries has prognostic value in pregnancies with hypertensive 
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complications, but no additional predictive value has been shown for in pregnancies 
with diabetes (104-106).   
No correlations were found between resistance in the umbilical- and middle cerebral 
arteries and maternal glucose levels in PGDM pregnancies (107, 108).  Whether 
maternal diabetes affects the umbilical artery velocity waveforms is unclear (92, 95, 
109).  Maruotti et al. showed that in pregnancies with type I diabetes, lower 
pulsatility index in the umbilical artery was associated with macrosomia (110).  The 
authors related this to typical changes found in PGDM placentas (111). 
Distinct structural and functional changes of the placenta are associated with diabetes 
in pregnancy.  The placenta is commonly heavier, the placental-/fetal weight ratio is 
increased (112-114) and typical histological findings are villous immaturity and 
enhanced angiogenesis (111).  Nutrient transport across the placenta is regulated by a 
range of hormonal and metabolic stimuli and may contribute to fetal nutritional 
oversupply in the presence of PGDM (115).  
Few studies report on fetal venous flow in diabetic pregnancies.  Olofsson et al. 
examined the blood flow distribution in PGDM pregnancies and found; larger UV 
flow early in the third trimester, increased flow to the lower extremities and reduced 
flow to the viscera (116).  Boito et al. found no difference in UV volumes in 
pregnancies with insulin dependent diabetes, but UV flow adjusted for fetal weight 
was reduced compared to a low risk group (92).  Stuart et al. showed that the DV 
pulsatility index was commonly higher in diabetic pregnancies than in low-risk 
populations and this positively correlated with HbA1C (117).  Still, the sensitivity of 
DV velocimetry to predict adverse perinatal outcomes in PGDM pregnancies remains 
unclear, with positive- and negative predictive values of 32% and 88% respectively 
(118, 119).   
Excess glucose metabolism caused by hyperglycemia and hyperinsulinemia 
accelerates the fetal oxygen consumption in diabetic pregnancies (120, 121).  In 
addition, larger body mass in LGA fetuses increases the oxygen demand.  Reduced 
materno-placental oxygen supply and increased fetal oxygen consumption results in 
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upregulation of placental growth factors and leptin, possibly affecting the fetal body 
composition (122-124).  In diabetic pregnancies the risks related to hypoxemia are 
increased, but the placentae or fetuses do not exhibit the ultrasound and Doppler signs 
typically present in pregnancies with placental insufficiency and intrauterine growth 
restriction.  Thus our clinical tools to identify fetuses at risk come in short in 
pregnancies with PGDM.   
Continuous focus on pre-conception counselling, compliance and glucose control can 
possibly reduce the burden of complications in pregnancies with PGDM (15).  Still, 
almost 50 years after the Pedersen hypothesis was published, the mechanisms causing 
increased risks in pregnancies with PGDM are partly unknown.  
Maternal glycemic control and fetal glucose 
Glycated haemoglobin, HbA1C, is used as an indicator of long-term glycemic control 
during the preceding two to three months (125).  Although HbA1C does not give a 
complete picture of maternal hypo- or hyperglycemia, it is recommended as a 
secondary clinical measure of glycemic control in pregnancy, in addition to self- or 
continuously monitored glucose (126).  HbA1C is lower in healthy pregnant than in 
non-pregnant women; the upper normal limit in late pregnancy is 5.8% (40 
mmol/mol) (127).  The Norwegian clinical guidelines for PGDM pregnancies 
recommends measuring HbA1C every four weeks; pre-pregnancy HbA1C should be 
<7.0% (53mmol/mol), and second and third trimester HbA1C <6.0% (42 mmol/mol) 
(128).  Lowering the HbA1C further may cause more frequent episodes of 
hypoglycemia and thus the targets for women with PGDM are not set to the normal 
levels of HbA1C.in pregnancy (126). 
Glucose is the main energy substrate for the fetus, and since the fetus probably has no 
significant gluconeogenesis it depends on glucose transfer over the placenta (129, 
130).  To ensure fetal glucose availability, the maternal physiology adapts during 
normal pregnancy, by peripheral insulin resistance and increased hepatic glucose 
production (82, 131).  The fetal glucose concentration is dependent on several factors; 
the maternal-fetal glucose gradient, placental morphology and transport, the placental 
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and fetal blood flows, the placental glucose metabolism and the fetal hormones and 
metabolism (77, 132-134).  Through “the fetal glucose steal phenomenon”, early 
establishment of fetal hyperinsulinemia and consequently lower fetal glycemic levels, 
in addition to maternal hyperglycemia, creates a higher glucose flux gradient across 
the placenta (135, 136).  Exaggerated “fetal glucose steal” in diabetic pregnancies 
may partly explain why the risk of large for gestational age offspring remains high in 
pregnancies with seemingly good glycemic control. 
1.2.4 Maternal weight and weight gain in pregnancy 
Maternal gestational weight gain varies considerably among women and is 
attributable to the uterus and its contents, larger breasts and the increased blood- and 
extracellular volumes.  In sum, the placenta, fetus and amniotic fluid comprise 
approximately 35% of the total gestational weight gain (137).  In addition, the 
deposition of new fat and protein make up the maternal reserves.   
IOM guidelines 
The Institute of Medicine (IOM) has provided a guideline for gestational weight gain 
(GWG) that is widely accepted (138, 139), also by the Norwegian health authorities 
(140).  The IOM guideline supplies GWG recommendations for each category of pre-
pregnancy body mass index (BMI); underweight, normal-weight, overweight and 
obese, and discusses in detail the challenges in pregnancy care created by “the obesity 
epidemic” (Table 1) (138).  The guideline does not specify any GWG 
recommendations in pregnancies with diabetes, and the committee encourages further 




Table 1 Body mass index categories and gestational weight gain 
recommendations 
Pre-pregnancy body mass index 
(kg/m2) 
Total gestational 




Underweight (<18.5) 12.5 – 18.0 0.44 – 0.58 
Normal weight (18.5 – 24.9) 11.5 – 16.0 0.35 – 0.50 
Overweight (25 – 29.9) 7.0 – 11.5 0.23 – 0.33 
Obese (>30) 5.0 – 9.0 0.17 – 0.27 
Institute of Medicine (IOM) recommendations for total weight gain during pregnancy and 




 trimester), by pre-pregnancy Body Mass Index 
(BMI) (138). 
Numerous studies report that pregnant populations are becoming increasingly 
overweight and obese, and that these are factors associated with adverse pregnancy 
outcomes.  In a Norwegian population-based study (1999 – 2009) 22.3 % of women 
were overweight and 9.1% were obese in pregnancy (141).  The maternal BMI and 
weight gain in pregnancy were positively associated with birthweight and BMI of the 
child at 3 years of age (142).  The Medical Birth Registry reported pre-pregnancy 
BMI in 74% of all births in Norway in 2017; 4.3% of women were underweight, 
62.4% normal weight, 21.7% overweight and 11.6% obese (143).  
BMI, weight gain and the fetal liver  
Increased birthweights suggest that the trans-placental transport of fuels, such as 
glucose and fatty acids, is increased in pregnancies with obesity and excess GWG.  In 
early pregnancy fetal subcutaneous fat is not yet developed and it has been proposed 
that the fetus therefore must utilize the liver for the storage of excess energy (144).  
Neonates of obese mothers with GDM have 68% higher hepatocellular lipid levels, 
and in GDM pregnancies there is a positive association between pre-pregnancy BMI 
and neonatal hepatic fat in both normal-weight and obese women (145).  
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In a population of uncomplicated pregnancies, Haugen et al. found that in mothers 
with low skinfold thickness, the fetal umbilical liver flow was increased, and 
introduced the concept of “fetal liver-sparing”.  This strategic adaptive response 
increase the offspring fat stores in preparation for postnatal conditions with restricted 
nutrient supply (146), and such liver-sparing is thought to have consequences for later 
health risks (60).  Low pre-pregnancy BMI was not associated with umbilical venous 
flow distribution in the longitudinal study constituting our low-risk reference group 
(45).  However, GWG had an impact on the venous flow distribution in the fetal liver, 
with relatively high flow of UV blood to the right liver lobe in women with high 
GWG.  
BMI and weight gain in PGDM pregnancies 
Maternal BMI is generally higher in type 1 DM pregnancies (16).  In an unselected 
Danish population, 43% of the pregnant women with type 1 DM were overweight or 
obese, and 54% had excessive GWG defined by the IOM criteria (147).  In PGDM 
pregnancies, high BMI is associated with increased risk of cesarean section, 
congenital heart malformations, preterm birth, LGA and admission to neonatal 




The Doppler principle has been exploited in technology since its discovery by 
Christian A. Doppler in 1843.  Ian Donald and co-workers were able to produce static 
ultrasonographic images and published in 1958 on the use of ultrasound in obstetrics. 
The group of FitzGerald and Drumm is recognized as the first to publish on the 
clinical use of fetal Doppler in1977(149).  Surely, grey scale imaging and Doppler 
ultrasound have led to important advances in fetal medicine since (150). 
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1.3.2 Gray scale ultrasound 
Sound waves with frequency above 20 kHz are called ultrasound and are above the 
range of human hearing.  The images displayed on the screen are recorded reflections 
of the ultrasonic waves directed from a probe towards tissues.  The strength of the 
reflections from different tissues is displayed as graded brightness in the images 
created. 
Penetration and resolution affects the quality of the displayed ultrasound images.  
Impedance is the loss of ultrasonic wave energy due to tissue resistance and is 
dependent on tissue density.  The penetration is affected by both the tissue impedance 
and frequency of the ultrasound.  High penetration can be obtained by reducing the 
frequency.  Thus, in obstetric ultrasound imaging, low frequencies (2.5 -3.5MHZ) are 
commonly used to visualize the fetus, deep in the abdomen.  However, low frequency 
reduces the resolution of ultrasound images and the sonographer should be aware of 
this accommodation. 
Image quality also depends on the surface of the tissues in contrast to the surrounding 
organs.  The fetal vessel walls are smooth structures yielding a strong reflection.  
Small vessels, like the DV, can be clearly defined when insonation of the ultrasonic 
beam is kept close to perpendicular to the vessel walls (Fig: 6A, 7A and 7C). 
1.3.3 Doppler  
The Doppler effect is the change in wave frequency when the transmitter and 
reflector move relative to each other.  If the reflector, i.e. blood cells in a vessel, 
moves toward the ultrasound source, the ultrasound waves will be compressed, and 
the frequency increased.  This phenomenon is exploited in Doppler ultrasound, to 
measure blood flow direction and velocity.  
For optimal measurements of velocity, the angle of insonation should be aligned with 
the vessel (angle of 0°).  To illustrate, if the angle is perpendicular to the flow 
direction (90°), the flow velocity will be estimated to zero.  The effect of the 
insonation angle diverting from 0° is expressed by a cosinus function, thus a 30° 
angle imposes only 6% error.  An angle of insonation within the range of 0 – 30 ° is 
 31 
therefore commonly accepted in velocity measurements for clinical and scientific 
purposes (151). 
Continuous wave (CW) Doppler is extensively used for external fetal heart rate 
detection, but does not provide information on blood flow velocities.  In pulsed-wave 
(PW) Doppler, short bursts of ultrasound waves are utilized to determine distance and 
this allows targeting a small area, or sample volume, with high resolution.  
Information from the Doppler analysis can be presented in color imposed upon the 
grey scale image.  Color Doppler gives a rough visualization of speed and flow 
direction.   
Aliasing, or the Nyquist effect, occurs if the maximum shift in wave frequency 
registered by the Doppler exceeds half the pulse repetition frequency of the PW and 
color Doppler system.  The distorted color image that occurs can be useful for 
identification of the DV, and by adjustments of the baseline and pulse repetition 
frequency, the PW Doppler yields a blood flow analysis.   
1.3.4 Blood flow calculations 
In this thesis, blood flow refers to volumes (mL/min).  In the calculation of blood 
flow (Q), the distribution of blood velocity is assumed to have a parabolic profile 
(Fig. 5) in the vessel lumen, and flow is calculated by the formula: 
Q=π(D/2)²hTAMXV 
D is vessel diameter, h is the velocity profile factor and TAMXV is the time average 
maximum flow velocity.  The velocity profile factor is an expression of the parabolic 
shape of the blood velocity across the vascular lumen.  The blood velocity profile is 
partly blunted in the DV and h is therefore higher than in the low velocity veins (152-
154); h=0.5 for UV and PV, and h=0.7 for DV (23).  
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Figure 5  Blood flow in the vessel lumen (red arrows). The velocity profile (blue) is 
partially blunted in the ductus venosus corresponding to a ratio of 0.7, in the umbilical vein 
and portal vein the flow is parabolic with a ratio of 0.5.  
The inner vessel diameter (D) is measured and squared in the equation, thus the 
diameter has a larger impact on the flow calculated, than the velocity.  In order to 
minimize measurement error repeated diameter measurement is recommended.  
When D measurements in the UV, PV and DV are repeated (≥3 times), it has been 
shown that flow calculations in fetal vessels during the second half of pregnancy, are 
reproducible and valid (46, 155-157). 
1.3.5 Safety 
Gray scale ultrasound in the low intensity range used for fetal assessment is generally 
considered safe (158).  However, the number of ultrasound scans per pregnancy is 
probably increasing, and methods other than grey scale imaging have become more 
available.  Thus, the safety of fetal ultrasound should be under constant evaluation 
(159, 160).   
Systematic reviews report no harmful effects of fetal ultrasound in humans (161, 
162).  However, in some epidemiological studies on biological effects of prenatal 
ultrasound, the scanners had lower acoustic outputs compared with modern 
apparatuses.  Animal studies have shown effects on neuronal migration and reversible 
liver apoptosis at output energies used in obstetrics (163, 164).  It has been argued 
that the probe-to-organ distance, organ size and the length of gestation make the 
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relative ultrasound power difficult to compare between these experimental animal 
studies and human pregnancies (159).  In one randomized controlled trial of low-risk 
pregnancies, a group exposed to continuous Doppler of fetal vessels (five sessions), 
was compared to a control group examined by grey scale ultrasound in gestational 
week 18 only (165).  No beneficial effects of assessing blood velocities were 
demonstrated, but a significantly higher risk of growth restriction was found in the 
intervention group.  Another randomized fetal Doppler study did not demonstrate a 
similar increased risk of fetal growth restriction (166).  Although fetal diagnostic 
ultrasound has been used extensively during the last 3 decades, the only consistent 
outcome is a weak association between ultrasound screening and left-handedness in 
boys (167). 
The ALARA principle states that exposure time and acoustic output should be kept as 
low as reasonably achievable consistent with obtaining diagnostic information.  To 
assess the risks during an examination, the thermal index (TI) and mechanical index 
(MI) are recommended indicators (160).   
The MI is an expression of the non-thermal bio-effects of ultrasound, most 
importantly the expansion and collapse of bubbles, a phenomenon called cavitation. 
This has not been demonstrated in humans, nevertheless, in all diagnostic ultrasound 
the MI should be kept below 1.0 (158). 
The energy of ultrasound waves can convert to heat depending on the tissue 
properties and the ultrasound exposure.  TI is defined as the ratio of the power used 
and the power needed to increase tissue temperature by 1°C.  TI does not take into 
account the exposure time or maternal body temperature.  Mineralized bones have the 
highest energy absorption, and beyond the 10
th
 gestational week TI for bone is the 
recommended index that the user should be aware of (168).  Exposure that produces 
no more than a 1.5°C temperature rise (given normal body temperature at 37°C) is 
considered safe (169).  Users should remain aware of the MI and TI indices during 
scanning and make sure guidelines are followed. 
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According to the Norwegian guidelines for PGDM pregnancies, first trimester 
ultrasound to measure CRL, a routine scan at 18 weeks and ultrasound for fetal 
biometry in week 24, 28, 32, 36 and 38 is usually performed, comprising a minimum 
of 7 sessions (170). 
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2. Aims of the study 
The overall aim of the thesis was to compare the longitudinal development of the 
venous liver blood flow in PGDM pregnancies with reference values from a low-risk 
population.  
More specifically, the aims were to describe the development in PGDM pregnancies 
of: 
Paper I 
 Umbilical venous  flow 
 Ductus venosus flow 
 Ductus venosus shunt fraction 
 Relation between DV flow and maternal glycemic control (HbA1C) 
Paper II 
 Left portal vein velocity 
 Portal venous flow 
 Portal venous fraction of total venous liver flow 
 Total venous liver flow 
 Umbilical venous liver flow 
 Associations between venous liver flow and maternal glycemic control 
(HbA1C) 
Paper III 
 Effect of venous liver flow on birthweight  
 Influence of BMI on venous liver flow  
 Influence of weekly GWG on venous liver flow  
 Association between BMI, GWG and birthweight 
 36 
3. Material and methods  
The study design was a prospective longitudinal observational study and the protocol 
was approved by the Regional Committee for Medical and Health Research Ethics 
(REK Vest 2011/2030).  
3.1 Study population 
In our region with 454,000 inhabitants, Haukeland University Hospital had 5169 
(mean) deliveries yearly during the study period (171).  All pregnant women with 
PGDM were referred our clinic for multidisciplinary follow-up, as soon as pregnancy 
was confirmed.  Between August 2013 and May 2016, all referred patients with 
PGDM (82 women) received written invitation to participate.  Of these, 12 had early 
fetal demise and in two pregnancies twins were detected at the first ultrasound 
examination.  This left 68 women invited, three women were unable to consent 
because of a language barrier, and 13 declined the invitation.  There was no protocol 
to register the individual reasons for those who declined the invitation.  However, 
several women reported this unencouraged; four lived geographically remote, four 
did not have time, three had concerns about ultrasound safety, one had a psychiatric 
disorder and one did not mention any cause for declining participation.  Three 
patients with type 2 DM withdrew after inclusion, leaving 49 PGDM in pregnancies 
in this study; 44 had type 1 DM and five women had type 2 DM.  Three women with 





Table 2  All women with pregestational diabetes mellitus (PGDM) referred to our 
institution during the study period were identified, all women that met the inclusion 
criteria were invited, 52 women (76% of the invited) agreed to participate, 49 pregnancies 
were followed longitudinally in the study;  DM, diabetes mellitus. 
 
3.2  Measurements 
At the first visit around week 9 (median GA 9.4, range 6.7 – 20.1), background and 
health information was collected systematically, describing ethnicity, education, 
employment, duration of diabetes, diabetic complications, co-morbidity, medication, 
82  
reffered pregnant 






44 type 1 DM 
5 type 2 DM 
12 early fetal demises 
 2 twin pregnancies 
13 declined invitation 
3 language barrier 
3 withdrew after week 9 
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menstrual cycle and obstetric history.  Gestational age (GA) was determined by 
measuring the crown rump length (172) with a vaginal probe (Vivid 7, GE Healthcare 
Vingmed Ultrasound, E8C, 8 MHz).  
Blood samples were collected at each visit and in the present study we used the 
results from the HbA1c analyses at inclusion.  The first HbA1C in pregnancy was 
collected at median GA 8.6 weeks (range 2.0 – 12.6).  For HbA1C values in the 2nd 
and 3
rd
 trimester, the means for each trimester were used in multilevel regression 
analyses (Paper I; Fig. 4 and Discussion). 
Information on the sex of the neonate, birthweight, mode of delivery, Apgar score, 
cord-blood gases and transfer to the neonatal ward was collected from clinical 
records.  Neonatal blood was collected from the heel 1 hour after delivery and the 
hematocrit (EVF) from this analysis is reported (Paper I and II; Table 1).  
3.2.1 Maternal weight and weight gain  
Maternal weight was measured at inclusion and in each trimester using a Tanita Body 
Composition Analyzer (BC-418).  The measured weights are discussed only briefly in 
this thesis.  Since equivalent data on measured weight in the first trimester were not 
available from the reference population, self-reported pre-pregnancy weight and 
height were used in the analyses.  The body mass index (BMI) was calculated by the 
formula BMI = weight (kg)/height (m)
2
. 
Weekly GWG was calculated by subtracting pre-pregnancy weight from the weight 
last measured before delivery, divided by gestational age at the last weighing.  
Weekly GWG was categorized according to pre-pregnancy BMI and the IOM 
guideline as;  insufficient;  appropriate;  excessive (139) (Paper III).   
3.2.2 Ultrasound and Doppler 
The ultrasound examinations were performed at gestational weeks 9, 20, 24, 28, 32, 
and 36 using an ultrasound system (Vivid 7, GE Healthcare Vingmed Ultrasound, 
Horten, Norway) with an abdominal transducer (M4S, 2.0–4.3 MHz).  All ultrasound 
measurements were performed by three observers; 193 sessions by A.L, 20 by J.K. 
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and 11 by C.E.  During the first 6 months of the study, all Doppler and diameter 
measurements performed by A.L. were supervised by J.K. and during the whole study 
period J.K. or C.E. were consulted if assessments were difficult to obtain.  Measuring 
the UV, DV and LPV was prioritized if all examinations could not be performed 
within the time limit.  Each session lasted no more than 1 hour and the TI was kept 
below 1.0. 
Figure 6 A. The inner diameter of the umbilical vein was measured minimum three times, 
intra abdominally and before any branching. B. Perpendicular to this umbilical vein velocity 
was measured. C. The anatomy of the umbilical vein, ductus venosus and left portal vein. D. 
Left portal vein velocity 
 
The time-averaged maximum blood velocity (TAMXV) was measured in the 
umbilical vein, ductus venosus, left portal vein and portal vein (Fig. 6 and 7).  The 
angle of insonation was kept as small as possible, not exceeding 30° (in all vessels 
median angle correction was 0, range 0 - 30°).  At the same site perpendicular to the 
vessel wall, the inner vessel diameter (D) was measured at least three times (median 
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3, range 3 – 5 times) in the umbilical vein, ductus venosus and portal vein, with the 
mean of these measurements used for the analyses.  D was measured in magnified 
images, with color Doppler turned off, after identification of the vessel.  When 
analyzing the data, all outliers (defined as ± 2 SD or identified visually in scatter 
plots) were reexamined by A.L. and J.K. in ultrasound images, to make sure the right 
vessel was identified and that the correct velocities and D were used for analyses.   
 
Figure 7  A and C. The inner vessel diameters in ductus venosus and portal vein 
respectively, measured at least three times, in magnified images with the color Doppler 
turned off. B. Sagittal view angled from the neck towards the flow direction of ductus 
venosus. D. Portal vein velocity with a typical pulsatile flow pattern 
Blood flow (, mLmin–1) was calculated by the formula    	
   
.  The velocity profile parameter was   for the umbilical vein (UV) 
and the portal vein (PV) (46),   for the ductus venosus (DV) (152, 153).  
Umbilical venous liver flow (UVliver) was calculated asiver  UV DV, total 
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venous liver flow as liver  UV DV  PVand PV fraction (FPV) of the total 
venous supply to the liver wasPV    PV	liver.  
3.2.3 Estimated fetal weight 
Flow was normalized based on estimated fetal weight (EFW) as 	 (mL·min–
1kg–1).  Birthweight z-score was used to calculate the intrauterine estimated fetal 
weights at the time of examination, by extrapolation according to the longitudinal 
reference curve for estimated fetal weight (45, 173).   
3.2.4 Reference values 
Reference curves for the fetal flow variables had been created in a separate project 
describing the normal venous blood supply development of the fetal liver (36, 45, 46, 
174, 175).  In this longitudinal study, 160 women with low-risk pregnancies were 
included during the period August 2004 – July 2005.  Reasons for exclusion were 
twins, fetal malformations, chronic maternal disease (including diabetes) or 
complicated obstetric history.  No women were excluded during or after pregnancy 
and thus no selection occurred after inclusion. . 
The methods for calculation of estimated fetal weight, pre-pregnancy BMI and 
weekly GWG were identical in the present study population and the reference 
population. In the previously published reference curves, the association to GWG was 
not categorized by the IOM guideline (45), in contrast to Paper III of this thesis. 
3.3 Statistics 
3.3.1 Power 
Since the effects of PGDM on the outcome variables were not known, no power 
calculations were performed to calculate sample size for the present study.  Instead 
the sample size was based on previous studies of pregnancies with fetal growth 
restriction and fetal macrosomia (62, 67), demonstrating significant associations 
between fetal growth patterns and variation in the venous liver circulation in 
populations of 29 and 25 pregnancies, respectively.  We allowed for a lower success 
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rate and possibly smaller effects in the present study protocol, and increased the 
number of participants to 50 women. 
3.3.2 Statistical methods 
The mean curves were modeled according to gestational age using multilevel 
regression analysis (176).  In addition, z-scores for outcome variables in the PGDM 
and reference groups were compared using the independent-samples t-test with a 
significance cutoff of p≤0.05.  The relations between maternal first-trimester HbA1c 
and z –scores for DV flow velocity, DV flow volume and DV shunt fraction (Paper I; 
Fig 4), and of LPV velocity and PV fraction (Paper II; Fig 6), were assessed by 
multilevel regression analysis.  To test differences between independent subgroups 
within each population by BMI, GWG and flow tertiles, ANOVA was used (Paper 
III).  Also, log-likelihood was performed to assess whether adding BMI or GWG 
categories improved the model for fetal flow by gestational age.  The statistical 
analyses were done in the Statistical Package for the Social Sciences (version 24, 
SPSS, Chicago, IL) and the MLWin program (version 2.35, Centre of Multilevel 




4.  Results 
4.1 Maternal characteristics 
The characteristics of the study population are described in Table 3.  
There were no smokers in the study group.  Participants defined their ethnic identity 
by their own terms; in the type 1 DM group 39 were Norwegian, four from other 
European countries and one Norwegian with parents from Chile.  In the type 2 DM 
group one was Japanese-American, one Chilean-Norwegian, one from the Philippines 
and two Norwegian.  The level of education was categorized as ≤12 years, 13 – 16 
years or ≥17 years; three, 22 and 20 women reported this respectively.  This 
information was missing in four pregnancies.   
Maternal BMI and GWG categories in the reference and PGDM populations are 
presented in Paper III; Supplementary Table 1.  The categories were not similarly 
distributed in the two populations (Fig 8).  
No adverse effects caused by participation in the study were registered, although 
some experienced pelvic- or back pain or a transitory fall in blood pressure, during 
the ultrasound examination.  
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Table 3 Maternal characteristics in 49 pregnancies with pregestational diabetes 
mellitus 




















Continuous glucose monitoring 







 Median Range 
Maternal age at inclusion (years) 
Gestational week at inclusion 
Duration of diabetes (years) 
  Type 1 DM 






23 - 42 
6.7 – 20.1 
 
1 – 37 
4 - 15 
Pre-pregnancy weight (kg) 70 57 –  113 
Pre-pregnancy BMI 
Maternal weight gain 
24.86 
15.8 
19.82 -  44.14 
–5.0 -  33.1 
HbA1c at inclusion (%) 6.70 4.90 –  12.00 
Mean HbA1C 2
nd
 trimester (%) 
Mean HbA1C 3
rd
 trimester (%) 
5.87 
6.08 
4.33 – 7.57 
4.90 – 8.46 




Figure 8  Percent of participants in the body mass index (BMI) and gestational weight gain 
(GWG) categories in the low-risk reference population (blue) and pregestational diabetes 
(PGDM) population (green);  The number of participants in each category is summarized in 
Paper III, Supplementary Table 1. 
4.2 Pregnancy outcomes and neonatal characteristics 
The pregnancy outcomes and neonatal characteristics of the PGDM population are 
presented in Paper I-III, Tables 2. The mean birthweight z-score was -0.06 in the 
reference population and 1.05 in the PGDM population (mean difference 1.11, 
p<0.001).  
The mean gestational age at delivery was 40.3 weeks in the reference population and 
37.8 weeks in the PGDM population (p<0.001 tested by independent sample T-test).  
In the reference group 9.4% were delivered by Cesarean section compared to 44.9% 




Figure 9  Birthweight z-scores boxplot in the low-risk reference population (blue) and the 
pregestational diabetes PGDM population (green) 
4.3 Main results 
4.3.1 Umbilical vein 
The UV flow was higher in PGDM pregnancies, and this was due to larger UV 
diameters in the PGDM compared with the reference group (Paper I; Tables 3 and 
S1).  Normalized UV flow was smaller, with a blunted development curve near term 
(Paper I; Fig. 1b).  
4.3.2 Ductus venosus 
The DV flow, normalized DV flow and DV shunt fraction were reduced in PGDM 
pregnancies (Paper I; Table 3, Fig 2 and 3).  The DV velocity reference curve has 
been published earlier (174), while the mean DV diameter for the reference 
population was calculated for the present study (Paper I; Appendix) (1).  The DV 
diameters were larger and the DV velocities lower in the PGDM group, compared 
with the reference.  However, at 36 weeks of gestation, the mean DV diameter z-
scores were similar between the populations.  Thus, the reduced DV flow in the 
PGDM population near term was mainly due to lower DV flow velocities (Fig. 10). 
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 Figure 10  Longitudinal observations of the ductus venosus diameter (mm; millimeter) 
and time averaged maximum velocity (TAMXV) in 49 pregnancies with pregestational 
diabetes (red circles) plotted on top of the reference curve; low-risk (black lines; mean (thick 
line), confidence interval (thin lines) and 5-95 percentiles (dotted lines)) 
4.3.3 Venous liver flow 
The umbilical venous flow to the liver (QUVliver), total venous liver flow (Qliver) and 
left portal vein (LPV) blood velocity (TAMXV) were higher in the PGDM group.  
Normalized PV flow and normalized total venous liver flow were lower in PGDM 
pregnancies after 30 gestational weeks compared with the reference values (Paper II; 
Table 3).  
4.3.4 BMI, gestational weight gain and fetal liver flow 
In PGDM pregnancies, the overweight BMI category had higher umbilical venous 
liver flow flows than in the normal- and obese weight categories.  BMI had a smaller 
impact on fetal flows in the reference population (Fig. 11a and Paper III; Table 2).  
Weekly gestational weight gain category was associated with altered fetal flow 
developments in the PGDM population only.  There was a graded positive response 
to GWG, and those with excessive GWG had the highest umbilical venous liver flow 
(Fig. 11b and Paper III; Table 3). 
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Figure 11  Longitudinal observations of the umbilical venous liver flow, umbilical venous 
liver flow (mL/min), during the second half of pregnancy in a low-risk population (black) 
and a population with pregestational diabetes (red), analyzed by log-likelihood test for a) 
BMI categories; normal weight, overweight and obese and b) Gestational weight gain 
(GWG) categories; insufficient, appropriate and excessive 
4.3.5 Fetal flow and birthweight 
Umbilical venous flow distribution was associated with birthweight in both the 
reference and PGDM populations, but the effect was more pronounced in pregnancies 
with PGDM.  There was a graded positive relation between LPV velocity, UV flow, 
total venous liver flow, umbilical venous liver flow and birthweight (Paper III; Table 
1). 
4.3.6 Glycated hemoglobin, HbA1C 
In PGDM pregnancies, first trimester HbA1C was positively related to LPV velocity 
and negatively related to DV velocity, DV flow, DV shunt fraction and PV fraction of 
the total venous liver flow (Fig 12).  
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Figure 12  Fetal blood flow and relation to HbA1C. Relations between z-scores of the 
ductus venosus (DV) shunt fraction, time-averaged maximum left portal vein (LPV) flow 
velocity (TAMXV) and portal vein (PV) fraction, and first-trimester HbA1c in the study 
population. 
 
4.4 Measurement success rate  
In addition to the 49 examinations at inclusion (at mean gestational week 9.4), a total 
of 224 sessions were performed in gestational weeks 20, 24, 28, 32 and 36; median 5 
sessions per participant, range 2 – 6.  Due to preterm deliveries, 9 women were not 
examined in week 36. 
Missing values for the ultrasound variables are summarized in Table 4.  There were 
no extra missing values for the normalized flows since birthweight and gestational 
age at examination was registered in all pregnancies.  The reasons for missing values 




















z-score DV shunt fraction
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(maximum one hour of fetal ultrasound), discomfort or hypoglycemia during 
examination, fetal movements and difficult examination conditions. 

















UV 15 6.7 22 9.8 32 14.3   
DV 66 29.5 33 14.7 86 38.4 101 45.1 
LPV   22 9.8     
PV 124 55.4 94 42 130 58 148 66.1 
Qliver     148 66.1   
QUVliver     101 45.1   
UV, Umbilical vein; DV, ductus venous; LPV, left portal vein; PV, portal vein; Qliver, total 
venous liver flow; QUVliver, umbilical venous liver flow; n, number of missing values; 
TAMXV, time average maximum flow velocity 
When the study population was divided into two groups (by missing and non-missing 
values) and compared by independent sample t-test, maternal BMI at inclusion in the 
missing data group was significantly higher than in the non-missing group (Tab. 5). 
HbA1C at inclusion was not different in the missing vs. non-missing groups for any of 
the flow variables. 
  
 51 
Table 5 BMI and HbA1C in the missing vs. non-missing data groups 
  n   










































































*Difference of the means tested by independent sample t-test. Umbilical vein, UV; ductus 
venous, DV; left portal vein, LPV; portal vein, PV; total venous liver flow  
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4.5 Type 1 and type 2 diabetes mellitus 
Since type 1DM and type 2DM are different diseases, we repeated the analyses with 
the results from pregnancies with type 2 DM excluded, to test if this would 
significantly change our findings.  The main outcomes were explored (independent 
sample t-test between type 1 DM pregnancies and the low-risk group) and the mean 
DV flow z-score was no longer significantly different between these groups (Table 6) 
(week 24 – 36).  When DV flow after gestational week 34 was analyzed, the mean z-
score was significantly lower in the type 1 DM group (mean z-score difference -0.64, 
p=0.009) compared with the reference group. 
Table 6 Umbilical venous and fetal liver blood flow in pregnancies with type 1 





















(-0.09 – 0.08) 
 
0.001 
PGDM 174 0.44 













(-0.53 – 0.11) 
 












(0.29 – 0.87) 
 
Umbilical venous 





(-0.12 – 0.06) 
 
<0.001 
PGDM 111 0.38 
(0.10 – 0.77) 
 
Total venous  






(-0.09 – 0.08) 
 
<0.001 
PGDM 69 0.595 
(0.14 – 0.92) 
n, number of observations; Mean z-score, mean of all flow measurements week 24 – 36; CI, 
confidence interval 
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5.  Discussion 
5.1 Principal findings 
The development of the UV, DV and venous liver flow were different in pregnancies 
with PGDM compared with low-risk pregnancies; the DV shunting was reduced near 
term and UV flow to the liver was increased.  Although the UV and total venous liver 
flows were increased before 30 gestational weeks, the total venous liver flow did not 
match third trimester fetal growth in pregnancies with PGDM.  First trimester HbA1C 
was positively related to the umbilical venous liver flow, and negatively to the DV 
shunting.  Maternal BMI and GWG had a greater impact on fetal venous liver flow, 
and umbilical venous liver flow had a larger effect birthweight, in PGDM- compared 
with low-risk pregnancies.  
5.2 Methodological considerations 
5.2.1 Ethical aspects 
Participation was voluntary and withdrawal possible at any time. Examinations were 
time consuming and some women commented this.  No adverse effects were 
registered, and in case of time limits or discomfort, the ultrasound examination was 
halted.  Although three women withdrew after the examination in week nine, all other 
participants remained in the project until birth.  The low withdrawal rate probably 
indicates that participation was acceptable to the women. 
Information about objectives, procedures and safety of the study was accessible 
online (177).  Participants could leave feedback by email any time during the study 
period.  These measures were taken to ensure that the consent was informed, and that 
patient involvement was possible.   
The protocol was up to date with publications and guidelines on safety (158, 160, 
162).  Current knowledge supports that this study was safe.  However, possible long-
term effects of fetal ultrasound have not been studied prospectively.  Thus the 
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ALARA principles for fetal ultrasound were followed strictly.  The duration of the 
examinations never exceeded one hour.     
5.2.2 The study and reference populations - selection, representativeness 
and generalizability 
The terms reference population and reference values are used in the present study 
although the collection of the reference data was done as a separate project and 
during a different time period (2004-2005) (36, 45, 46).  It may represent a limitation 
that the reference study was performed approximately 11 years before the present 
PGDM study.  However, the reference study was conducted in the same hospital and 
by the same research group.  Also, the examination techniques were identical, which 
are strengths that reduce the risk of variability due to differences in technique. 
The reference study aimed for recruitment of low-risk pregnancies.  No women were 
excluded after inclusion to avoid selection by pregnancy outcomes.  The distribution 
of pre-pregnancy BMI in the reference group was in concordance with reports form 
the Medical Birth Registry of Norway at the time of our PGDM study (2013 – 
2016)(178), and the distribution of birthweight in the reference group was also 
similar to the background population (179).  Pre-pregnancy BMI, weekly GWG and 
birthweights, as well as the flow variables, were normally distributed in the reference 
population.  Thus, the reference values were considered representative for low-risk 
pregnancies in Norway at the time of our study and suitable for comparison with the 
PGDM study group. 
The study population was an unselected group of PGDM pregnancies from our 
department.  Data from the women who declined the invitation were unavailable.  
Thus some degree of selection bias cannot entirely be ruled out.  However, 75 % of 
the invited women participated and we did not identify any systematical reasons for 
declining participation.  We therefore conclude that t study group is representative of 
PGDM pregnancies in Norway. 
The study population received clinical follow up according to Norwegian and 
internationally accepted guidelines (170).  This substantiates that the results are 
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generalizable in similar clinical settings.  In our clinic the overall rate of cesarean 
deliveries is generally low (12.7% during the study period) (180).  However, the 
cesarean frequency in our PGDM study group was 44.9% and similar to 46% in a 
large Swedish population (16).  Thus, the management of labor in the PGDM study 
group was probably not different from clinics that are relevant for comparison.  
There were more missing data in the study- compared with the reference population 
(Table 4)(175).  Within the study group there was a selection by BMI, with higher 
BMI in the missing-data group (Table 5).  This was discussed in Paper I-III and 
interpreted as a possible selection bias towards data from a leaner PGDM population.  
Such a selection would likely lead to less significant differences between the 
populations.  Nevertheless, this selection may represent a weakness because the study 
population is then less representative of all PGDM pregnancies.  
HbA1C did not influence the examination success rate and thus a selection by HbA1C 
was unlikely (Table 5). 
Women with type 1 and type 2 DM were invited.  Only 5 women with type 2 DM 
participated in the study while the rest of the participants had type 1 DM (Table 3).  
Glycemic profiles of women with type 1 DM and type 2 DM are different, and when 
studied with continuous glucose monitoring, women with type 2 DM spent less time 
hyper- and hypoglycemic during pregnancy compared with type 1 DM (181).  Still, 
epidemiological studies have shown that the risk of adverse outcomes are similar in 
pregnancies with type 1 DM and type 2 DM (182).  One may argue that the optimal 
design would be to study pregnancies with type 1 DM and type 2 DM as separate 
groups.  However, we chose not to exclude women with type 2 DM, and the main 
results did not change when measurements from the type 2 DM subgroup were 
excluded from the analysis (Table 6).  
5.2.3 Validity and reliability of fetal flow 
Validity refers to whether a study measures what it aims to measure.  Reliability is a 
measurement of error, and reflects the difference between the observed value and the 
“true” value.  The reliability is high when measurement errors are small and different 
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observed values are optimally a reflection of genuine differences between 
measurements, not due to random or systematic errors (183).  
Measurements should be repeatable and reproducible.  This can be evaluated by 
estimating the intra – and inter-observer variation.  This was done in the studies that 
established the measurement techniques and constructed the reference values; For the 
ductus venosus and LPV velocities, the intra and inter-observer variations were low 
(36, 174).  For the portal vein, intra-observer variation was low for both velocity and 
diameter (46). 
The calculation of blood flow is based on flow velocities and vessel diameter.  Since 
experimental invasive procedures in human fetuses are not ethically acceptable, 
models have been used for validation of the Doppler ultrasound technique to calculate 
fetal flow (184, 185).  In sheep they found no differences between triplex mode 
ultrasound and steady-state diffusion measurement of umbilical venous flows.  In 
addition, Babera et al studied the intra- and inter-observer variability for these 
measurements in human pregnancies and concluded that valid and reliable 
measurements of umbilical vein blood flow can be produced by this technique. 
Doppler ultrasound is widely used for fetal blood velocity measurements in research 
as well as clinical settings.   
The fetal vessel diameters are not commonly measured in clinical settings, and since 
the diameter is squared in the blood flow equation, the accuracy of this value is 
crucial.  To reduce measurement error, each vessel diameter was measured at least 
three times, and the mean of the measurements was used (155, 186).  Supervision by 
J.K. during the first 6 months, consulting ultrasound experts from the research group 
in case of difficult examinations, and the reassessment of all outlier values, were 
measures taken to secure the validity of data.  
The number of missing values reflects that optimal measurements could be difficult 
to obtain in our study group.  But the fact that calculated flow in the study population, 
examined mostly by one examiner (A.L), did not deviate more from the reference 
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curves, indicates that the data are reliable.  The confidence intervals were larger in the 
study group than in the reference group, and this is probably partly due to the smaller 
study population.  It is also possible that measurement errors were larger in the study 
group, due to participant characteristics that made measurements technically more 
challenging (Table 4). 
The techniques applied are described in publications as methods to measure fetal flow 
(23, 45, 46, 157, 175).  It should be emphasized that the present study was performed 
in a scientific setting and that we do not suggest the methods for clinical use.  This is 
of importance since we have not studied the diagnostic value of calculating fetal 
venous flow in PGDM pregnancies (183).  
5.2.4 Glycated hemoglobin as a measure of glycemic control 
We used HbA1c as an expression of maternal glycemic control, and analyzed the 
relation between HbA1C and the distribution of umbilical venous flow.  The umbilical 
venous liver flow (expressed by LPV velocity) related positively to HbA1C (Figure 
12).  The effect of augmented umbilical venous liver flow was higher birthweights 
(Paper III).  We did not find that HbA1C differed between the BMI and GWG 
categories, although birthweights did (Paper III, Supplementary Table 2).   
This complies with studies showing increased risk of macrosomia in PGDM 
pregnancies, despite HbA1C within the recommended levels (79, 147).  Although 
HbA1C is a measure of glycemic control in women with PGDM, it does not fully 
reflect the glucose variability in women with PGDM (126, 135, 181). 
5.2.5 Body mass index and gestational weight gain in pregnancies with 
diabetes mellitus  
The IOM guidelines use pre-pregnancy BMI categories to advice maternal weight 
gain in pregnancy.  These criteria are widely adopted and have been used in 
publications on diabetes in pregnancy (138, 147, 148, 187).  There are some 
weaknesses however, as BMI does not reflect the fat percentage, fat distribution, the 
muscle mass or oedema.  Rasmussen et al emphasize that the evidence for the IOM 
recommendations regarding weight gain in pregnancies is not strong (138). 
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5.2.6 Comparison with other studies 
Fetal venous flow in pregnancies with PGDM has been studied by Olofsson et al. and 
by Boito et al (92, 116).  The former showed that in women with diabetes in 
pregnancy, UV flow was higher in gestational weeks 26-34, but not different than 
their reference population from week 35.  This is in concordance with our present 
study as discussed in Paper I.  Furthermore, Olfosson et al. found that flow to the 
lower extremities increased from 35 gestational weeks in the diabetic group.  We did 
not examine flow to the extremities, but the reduced PV flow found in our study 
showed that flow to the viscera was low after 30 weeks of gestation, and this was 
even more pronounced when PV flow was normalized for fetal weight (Paper II, 
Figure 1).  Prioritized flow to the lower extremities, at the expense of the visceral 
flow, corroborates with these findings.  
Boito conducted a cross-sectional PGDM study (gestational week 18 – 36), and 
reported no difference in the UV flow.  In contrast, we found larger mean UV flow in 
PGDM compared with low-risk pregnancies, with non-overlapping CI in weeks 28 – 
34.  The differences in design of Boitos study and the present can explain the 
different results.  However, both studies describe significantly reduced UV flow 
when normalized for fetal weight (Paper I) (92).   
The larger liver volume found by Boito et al could relate to higher venous liver flows 
as described in our Paper II.  
5.3 Psychological aspects 
With permission, one participant with type 1 DM is quoted: Worries for the child’s 
well-being and development, for my own health through pregnancy and for the 
possible complications from birth – complications that my efforts might not prevent - 
increased the stress and this could contribute to less optimal regulation.    
The study was not designed to describe the emotional stress that women with diabetes 
might experience during pregnancy.  Nevertheless, 410 hours were spent during the 
study period consulting the women (mean 8.5 hours per pregnancy).  The impression 
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from these consultations was that PGDM is challenging to cope with.  Diabetes is 
associated with lower psychological well-being during pregnancy, and women with 
diabetes in pregnancy carry a higher risk of post-partum depression symptoms (188).  
However, in a Danish study of PGDM, women with lower GWG and HbA1C had a 
slight improvement in mental quality of life during pregnancy (189) .   
The risk of increasing stress should be considered when counselling women with 
PGDM.  How to communicate knowledge about lifestyle, weight gain, glucose 
control, pregnancy outcomes and the possible Developmental Origins of Health and 
Disease (DOHaD) effects, without causing anxiety, should be discussed and studied 
further.  
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6. Conclusion and future aspects  
This longitudinal study adds new knowledge by describing the development of fetal 
venous liver flow during the last half of PGDM pregnancies, 
In pregnancies with PGDM, the reduced DV shunting near term may pose an 
augmented risk during hypoxic challenges in late pregnancy and during labor. We 
thus suggest that further studies explore the usefulness of DV Doppler measurements 
to identify fetuses at risk in PGDM pregnancies.  
The finding of increased umbilical venous liver flow might partly explain the 
increased risk of macrosomia, even in well-regulated patients (79).  However, unlike 
non-diabetic fetuses, venous liver flow did not match fetal growth in PGDM 
pregnancies.  The possible consequences of altered venous liver flow for neonatal 
body composition and postnatal growth, is a relevant subject to study further. 
We observed that blood flow changes accelerated during the third trimester.  The last 
measurements in the study were performed around gestational week 36.  Future 
research should investigate the blood flow development close to delivery. 
Our study identifies the umbilical venous liver flow as an important mechanism by 
which maternal BMI and gestational weight gain influence birthweight in PGDM 
pregnancies.  Measures to decrease the risk of macrosomia in PGDM pregnancies are 
called for.  Future research could further explore the effects of restricted weight and 
weight gain on the fetal hemodynamic development in pregnancies with PGDM. 
The present study is part of a larger research project, established and organized by 
our research group.  Maternal anthropometrics, nutritional intake, salivary cortisol 
and blood samples were collected at each visit.  Blood was also drawn for bio-bank 
preservation in every trimester, and fetal ECG Holter monitoring was performed 
twice.  Placental and umbilical cord tissue, and umbilical venous blood for our bio-
bank, was collected shortly after birth.  The placentas were examined by perinatal 
pathologists, and histology was described.  A neonatal echocardiography was 
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performed within 4 days after delivery.  Approximately 6 months after birth, blood 
samples were drawn from the mother and child for bio-banking and an Alberts Infant 
Motor Scale (AIMS) test assessed the child’s motor development.  This large amount 
of systematically collected data, combined with a detailed characterization of the fetal 
and pregnancy developments, permits for future projects to further explore the 
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Abstract
Introduction. Despite adequate glycemic control, the risks of fetal macrosomia
and perinatal complications are increased in diabetic pregnancies. Adjustments of
the umbilical venous distribution, including increased ductus venosus shunting,
can be important fetal compensatory mechanisms, but the impact of
pregestational diabetes on umbilical venous and ductus venosus flow is not
known. Material and methods. In this prospective study, 49 women with
pregestational diabetes mellitus underwent monthly ultrasound examinations
from gestational week 20 to 36. The blood velocity and the mean diameters of the
umbilical vein and ductus venosus were used for calculating blood flow volumes.
The development of the umbilical venous flow, ductus venosus flow and ductus
venosus shunt fraction (% of umbilical venous blood shunted through the ductus
venosus) was compared with a reference population, and the effect of HbA1c on
the ductus venosus flow was assessed. Results. The umbilical venous flow was
larger in pregnancies with pregestational diabetes mellitus than in low-risk
pregnancies (p < 0.001) but smaller when normalized for fetal weight
(p = 0.036). The distributional pattern of the ductus venosus flow developed
differently in diabetic pregnancies, particularly during the third trimester, being
smaller (p = 0.007), also when normalized for fetal weight (p < 0.001).
Correspondingly, the ductus venosus shunt fraction was reduced (p < 0.0001), most
prominently at 36 weeks. Therewere negative relations between thematernalHbA1c
and the ductus venosus flow velocity, flow volume and shunt fraction.
Conclusions. In pregnancies with pregestational diabetes mellitus, prioritized
umbilical venous distribution to the fetal liver and lower ductus venosus shunt
capacity reduce the compensatory capability of the fetus and may represent an
augmentedriskduringhypoxic challengesduring latepregnancyandbirth.
Abbreviations: DM, diabetes mellitus; DV, ductus venosus; EFW, estimated
fetal weight; PGDM, pregestational diabetes mellitus; TAMXV, time-averaged
maximum flow velocity; UV, umbilical vein.
Introduction
Pregnancies complicated by pregestational diabetes melli-
tus (PGDM) are associated with increased risks of perina-
tal mortality, congenital anomalies, macrosomia, preterm
birth, and fetal distress (1,2). According to the Pedersen
Key Message
In pregnancies with pregestational diabetes the umbil-
ical venous flow to the liver is increased at the
expense of ductus venosus shunting, possibly increas-
ing fetal vulnerability near term.
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hypothesis, fetal hyperglycemia and hyperinsulinemia
cause higher rates of macrosomia (3). Although strict gly-
cemic control can reduce mortality and morbidity (4),
the risk of adverse outcomes is higher than in non-dia-
betic pregnancies (5).
Identifying at-risk fetuses in diabetic pregnancies
remains challenging due to the inadequacy of diagnostic
tools (6). Umbilical artery Doppler ultrasound is widely
used in pregnancies with placental insufficiency, and eval-
uation of the ductus venosus (DV) flow velocity wave-
form has become an integral part of surveillance (7,8).
The DV pulsatility index is commonly higher in diabetic
pregnancies than in low-risk populations (9), but its use-
fulness in monitoring diabetic fetuses remains unclear.
Typical circulatory adaptations in PGDM pregnancies
have not been identified (10,11), with the exception of
one study finding that the umbilical vein (UV) flow was
larger early in the third trimester and decreased toward
term (12).
The distribution of the blood flow through the UV and
DV develop differently in fetuses with normal growth,
growth restriction, and macrosomia without maternal
diabetes (7,13). This suggests that the umbilical supply to
the liver plays a role in regulating fetal growth (13,14)
and fat deposition (15), with possible lifelong conse-
quences (16). The DV shunts oxygenated UV blood to
the fetal heart and brain, bypassing the liver (17), and
increased shunting serves as a protective mechanism
(18,19). In fetal lamb and humans with gestational dia-
betes, hyperglycemia leads to accelerated metabolism and
oxygen consumption, causing chronic fetal hypoxemia
(20,21). However, the UV blood distribution and DV
flow pattern in pregestational diabetic pregnancies have
not been reported previously.
We hypothesized that the fetal distribution of the UV
and DV flow is altered in PGDM pregnancies compared
with a reference population and that this is influenced by
the degree of maternal glycemic control. Thus, the aim of
this study was to describe the development of the UV
flow and its distribution to the fetal liver and DV in dia-
betic pregnancies, and to examine whether the distribu-




All pregnant women with PGDM [type 1 or type 2 dia-
betes mellitus (DM)] in our region are referred to Hauke-
land University Hospital, a tertiary center for
multidisciplinary follow up. All women with PGDM and
singleton pregnancies who presented at our hospital
between August 2013 and October 2016 were invited to
participate in this prospective longitudinal observational
study. The study protocol was approved by the Regional
Committee for Medical and Health Research Ethics (REK
vest 2011/2030), and 52 women (74% of those invited)
gave written consent: 43 participants had type 1 DM,
eight participants had type 2 DM, all of these received
gestational insulin treatment. Three participants with
type 2 DM withdrew after the first visit leaving a total of
49 PGDM pregnancies for statistical analyses. Gestational
age was determined by the crown–rump length measure-
ments using a vaginal transducer (E8C, 8 MHz) at the
first visit at approximately nine gestational weeks (22).
Second-trimester routine scans did not reveal any fetal
malformation in the study population. Information on
maternal HbA1c, neonatal sex, birthweight, mode of
delivery, Apgar score, cord-blood gases, and transfer to a
neonatal ward was collected from clinical records. The
study group was compared with reference ranges estab-
lished in a longitudinal study on 160 low-risk pregnan-
cies (564 observations for the UV and 536 observations
for the DV) during the second half of pregnancy (23,24).
Ultrasound examinations
The ultrasound examinations were performed at gesta-
tional weeks 20, 24, 28, 32, and 36 (at 20 weeks only the
UV was measured). Each session lasted no more than one
hour, and the thermal index was kept below 1.0. All
ultrasound measurements were performed by three obser-
vers (A.L., J.K. or C.E.) using an ultrasound system
(Vivid 7, GE Healthcare Vingmed Ultrasound, Horten,
Norway) with an abdominal transducer (M4S, 2.0–
4.3 MHz).
The time-averaged maximum flow velocity (TAMXV)
was measured in the intraabdominal part of the UV
and in the DV during fetal quiescence, with the angle
of insonation kept as small as possible, not exceeding
30° (median angle correction was 0, range 0–30°). The
inner vessel diameter (D) was measured at least three
times at the same site perpendicular to the vessel wall,
with the mean of these measurements used for the
analyses. D was measured in magnified images, with
color Doppler turned off, after UV and DV identifica-
tion. Blood flow volume (Q, mLmin1) was calculated
by the formula Q = p(D/2)²hTAMXV. Velocity profile
parameter h was 0.7 for DV and 0.5 for the UV. The
DV shunt fraction (%) was calculated as 100QDV/QUV.
Flow volume was normalized based on the estimated
fetal weight (EFW) as Q/EFW (mLmin1kg1) (25).
The techniques applied are identical with those used to
establish the reference ranges, and are described in
detail elsewhere (23,26).
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Statistical analyses
The sample size was based on previous studies (13,27)
demonstrating significant associations between fetal
growth patterns and variation in the venous liver circula-
tion. We allowed for a lower success rate and possibly
smaller effects when planning the present study, and
increased the number of participants from 30 to 50.
The mean and standard deviation values for the out-
come variables in the diabetic group were modeled
according to gestational age using multilevel regression
analysis. The absence of overlap in the 95% confidence
intervals of the mean indicates a statistically significant
difference between the study and reference (24) popula-
tions. In addition, z-scores for outcome variables in the
PGDM and reference groups were compared using the
independent-samples t-test with a significance cutoff of
p ≤ 0.05. The relations between maternal first trimester
HbA1c and DV flow velocity, DV flow volume, and DV
shunt fraction z-scores were assessed by multilevel regres-
sion analysis. The statistical analyses were performed with
the Statistical Package for the Social Sciences (version 24;
SPSS, Chicago, IL, USA) and the MLWin program (ver-
sion 2.35; Centre of Multilevel Modeling, University of
Bristol, Bristol, UK).
Results
The characteristics of the study population are described
in Tables 1 and 2. The median gestational age at birth
was lower and birthweights were higher in the study
group than in the reference population (24) (Tables 1
and 2). In the study group, 39% of the neonates were
macrosomic (birthweight >90th percentile for gestational
age) (25). The UV and DV flow velocities and diameters
were successfully measured in 85.8% and 77.2% of 225
examination sessions, respectively. The DV shunt fraction
could be calculated for 69.5% of the sessions.
The UV flow velocities in the study group did not dif-
fer significantly from those in the reference group
(Appendix S1). However, the mean UV diameter was lar-
ger in the PGDM group (mean z-score = 0.48,
p < 0.005), resulting in a larger UV flow volume in the
study group (Table 3), primarily during gestational weeks
25–31 (Figure 1a). When normalized for EFW, the UV
flow was smaller compared with that in the reference
population (Table 3), and in PGDM pregnancies the nor-
malized UV flow exhibited a significant blunting at the
end of the third trimester (Figure 1b).
The DV diameter was larger (mean z-score = 0.35,
p = 0.034) while the DV TAMXV was smaller (mean z-
score = 1.20, p < 0.005) in the study group than in the
reference (Appendix S2). However, at week 36 there was
no difference in the DV diameters (mean z-score = 0.31,
p = 0.40) but the DV TAMXV remained smaller in the
study group (mean z-score = 1.87, p < 0.005). In the
reference population, the DV flow volume increased stea-
dily from mid-gestation until term, whereas it was smaller
in the diabetic group (Table 3) and became progressively
blunted beyond 30 weeks of gestation (Figure 2a). The
normalized DV flow volume was significantly smaller in
the study group after gestational week 32 (Table 3,
Figure 2b).
In PGDM pregnancies, the degree of DV shunting was
significantly smaller during the second half of pregnancy
(Table 3). In the reference population this reached a min-
imum of 20% at 30 weeks of gestation (23), whereas it
was smaller in diabetic pregnancies both before and after
30 weeks, which constituted a strikingly different pattern
of development (Figure 3a).
There was a borderline significant negative linear rela-
tion between the DV shunt fraction at 36 weeks of gesta-
tion and the lactate concentration in the umbilical artery
at birth (B = 0.19, p = 0.051; Figure 3b).
Table 1. Maternal characteristics and outcomes in 49 pregnancies
with pregestational diabetes mellitus.
n %
Type 1 DM 44 89.8
Type 2 DM 5 10.2




Chronic hypertension 7 14.3
Preeclampsia 3 6.1
Preterm birth 15 30.6
Induction of labor 30 61.2
Normal delivery 20 40.8
Operative vaginal delivery 7 14.3




Maternal age at inclusion, years 31 23–42
Prepregnancy weight, kg 70 57–113
Maternal weight gain 15.8 –5.0 to 33.1
Prepregnancy BMI 24.86 19.82–44.14
HbA1c at inclusion 6.70 4.90–12.00
Individual mean HbA1c
b 6.12 4.86–8.24
Preterm birth, gestational age <37 weeks.
DM, diabetes mellitus.
aAcute cesarean section during labor.
bMean of all HbA1c measurements throughout each pregnancy.
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The DV TAMXV, DV flow volume, and DV shunt
fraction were negatively related to the first trimester
HbA1c (Figure 4). The multilevel regression analyses were
also performed for second and third trimester HbA1C,
with similar results for DV flow and shunting (data not
shown).
Excluding T2DM participants from the PGDM popula-
tion did not significantly change the results for the z-
score mean flow variables UV flow, normalized UV flow,
normalized DV flow or DV shunt fraction (univariate
analysis of variance), but the mean DV flow z-score was
no longer significantly different for the T1DM population
alone compared with the reference; 0.212 [95% confi-
dence interval (CI) 0.424 to 0.000, p-value = 0.071].
Discussion
This study found that the distribution of UV blood was
significantly altered in PGDM pregnancies, with a smaller
fraction of the UV blood directed through the DV and
relatively more to the fetal liver. This distorted develop-
ment of the UV distribution in PGDM pregnancies was
evident from mid-gestation but was particularly promi-
nent during the last weeks of pregnancy (Figures 1–3).
Our findings are partly in contrast with those of Boito
et al. (28) showing unaffected UV flow volumes in
PGDM pregnancies, but smaller normalized UV flow vol-
ume, in line with our present study. Olofsson et al. found
larger normalized UV flow in the early third trimester of
diabetic pregnancies, but like in our study group the nor-
malized UV flow decreased during the last weeks of preg-
nancy (12). The discrepancies between the studies might
be due to differences in methods and study populations.
The portocaval pressure gradient between the UV and
the vena cava inferior drives the perfusion of the fetal
liver and flow through the DV, and the DV blood veloc-
ity directly reflects this pressure (29). A reduced resis-
tance to flow in the portal system relative to the DV
would contribute to preferential UV distribution to the
liver (30,31). Greater UV distribution to the liver in
PGDM pregnancies could be related to increased liver size
Table 2. Neonatal characteristics and outcomes in pregnancies with
pregestational diabetes mellitus.
Median Range
Gestational age at delivery (weeks+days) 38+4 27+6 to 40+5
Birthweight (g) 3695 990–5990
Birthweight z-score 0.93 2.15 to 5.82
Umbilical cord acid-base data
Umbilical artery
pH 7.24 6.92–7.34
pCO2 (kPa) 7.88 5.80–12.40
pO2 (kPa) 2.19 1.16–3.47
Base deficit (mmolL1) 2.11 13.36 to 1.00
Lactate (mmolL1) 4.70 2.00–14.40
Umbilical vein
pH 7.30 6.89–7.44
pCO2 (kPa) 6.10 4.20–15.30
pO2 (kPa) 3.29 0.25–5.68
Base deficit (mmolL1) 2.36 10.98 to 0.15
Lactate (mmolL1) 3.50 1.80–12.80
Erythrocyte volume fraction 0.63 0.52–0.76
n %
Male sex 25 51
Operative delivery for intrapartum fetal distress 13 26.5
Metabolic acidosis at birtha 1 2
5-min Apgar score <7 1 2
Transfer to neonatal intensive care ward 20 40.8
Perinatal deathb 1 2
Malformationc 2 4
aMetabolic acidosis defined as an umbilical arterial pH of <7.0 and a
base deficit of >12.
bIntrauterine fetal death at gestational week 36. Autopsy showed UV
thrombosis and signs of acute asphyxia.
cOne neonate with sagittal craniosynostosis and one with congenital
heart defect (anomalous left coronary artery from the pulmonary
artery).
Table 3. Umbilical venous (UV) and ductus venosus (DV) blood flow z-scores in pregnancies complicated by pregestational diabetes mellitus
(PGDM) compared with reference values from a low-risk population.
Parameter Population Mean z-score 95% CI No. of observations p
UV flow (mLmin1) Reference 0.000 0.097 0.097 562 <0.001
PGDM 0.356 0.191 0.521 192
Normalized UV flow (mLmin1kg1) Reference 0.005 0.096 0.106 562 0.036
PGDM 0.230 0.414 0.046 191
DV flow (mLmin1) Reference 0.005 0.101 0.110 532 0.007
PGDM 0.332 0.539 0.125 138
Normalized DV flow (mLmin1kg1) Reference 0.005 0.104 0.114 532 <0.001
PGDM 0.614 0.818 0.410 137
DV shunt fraction (%) Reference 0.000 0.0821 0.0904 524 <0.0001
PGDM 0.510 0.8119 0.2006 125
CI, confidence interval; DV shunt fraction (%), (DV flow volume/UV flow volume)100; reference values from low-risk population (23).
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(28) and a larger vascular cross-section of the portal sys-
tem. A larger viscous resistance in the liver vasculature
due to polycythemia (Table 2) was expected (32), and
this would shift blood flow from the liver to the DV, but
the opposite situation was found in the present diabetic
pregnancies (Figures 2 and 3). This suggests that the
impact of fetal hyperglycemia on the circulatory regula-
tion of the fetal liver overpowers the physiological mecha-
nisms that would otherwise operate.
In fetal lamb, occluding the DV and forcing all UV
blood to perfuse the fetal liver, leads to increased liver
weight, cell proliferation, and differential fetal organ
growth (14). Up-regulation of the UV blood distribution
to the liver is believed to be an important mechanism
underlying the development of macrosomia and increased
fat accretion (15), and the present study has demon-
strated this flow pattern in PGDM pregnancies. However,
in macrosomia without DM, the UV flow volume
(a) (b)
Figure 1. Umbilical venous flow. Longitudinal observations of umbilical vein (UV) flow volume (a) and normalized UV flow volume (b) in 49
pregnancies with pregestational diabetes mellitus (red circles and lines) compared with a reference population (black lines). Mean (thick lines) and
95% confidence interval (thin lines) values are shown. [Color figure can be viewed at wileyonlinelibrary.com].
(a) (b)
Figure 2. Ductus venosus (DV) flow. Longitudinal observations of DV flow volume (a) and normalized DV flow volume (b) in 49 pregnancies with
pregestational diabetes mellitus (red circles and lines) compared with a reference population (black lines). Mean (thick lines) and 95% confidence
interval (thin lines) values are shown. [Color figure can be viewed at wileyonlinelibrary.com].
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accelerates during the third trimester, supporting the
increased growth velocity, whereas the DV flow volume
remains unchanged (13). This is at variance with the dis-
torted UV distribution in our PGDM group, in which
UV return from the placenta decreased (Figure 1a) and
DV shunting was reduced near term (Figure 3a). The UV
flow volume normalized for EFW was strikingly low dur-
ing late gestation, possibly signifying a relative discrep-
ancy between fetal demand and substrate availability
(Figure 1b) in our study group (13).
Fetuses of mothers without diabetes, consuming a diet
defined as imprudent, exhibits “liver-sparing” UV blood
distribution, with a larger UV flow to the liver and smal-
ler DV shunting at week 36 (33). Larger fetal abdominal
circumference was found to be associated with increased
UV flow after oral glucose loading in a low-risk popula-
tion (34). The negative relation between HbA1c levels and
the DV shunt fraction (Figure 4) in our study supports
the assumption that maternal metabolic factors and glu-
cose promote UV flow distribution to the fetal liver. Even
within the range of clinically acceptable glycemic control
(maternal first trimester HbA1c <7%), the DV shunt frac-
tion decreased significantly with increasing HbA1c (Fig-
ure 4). Although the use of HbA1c in pregnancy may
have limitations, the association between HbA1c and
plasma glucose is linear in most individuals (35). First tri-
mester HbA1c measurement gives information about
(a) (b)
Figure 3. Ductus venosus (DV) shunt fraction. (a) Longitudinal observations of DV shunt fraction in 49 pregnancies with pregestational diabetes
mellitus (red circles and lines) compared with a reference population (black lines). Mean (thick lines) and 95% confidence interval (thin lines)
values are shown. (b) Relation between umbilical arterial lactate at birth and DV shunt fraction z-score at gestational week 36 (n = 15). Missing
data for week 36 were due to premature delivery (n = 18), unsuccessful cord-blood lactate measurements (n = 13), and/or missing
measurements for calculating the DV shunt fraction (n = 20). [Color figure can be viewed at wileyonlinelibrary.com].
Figure 4. Ductus venosus (DV) shunt fraction and HbA1c. Relations
between the time-averaged maximum DV flow velocity (TAMXV), DV
flow volume, and DV shunt fraction and first trimester HbA1c. DV
flow velocity mean z-score = 0.6867 to 0.0010 (95% CI
0.00194836 to 0.00001008) HbA1c3 ln(HbA1c), DV flow volume
mean z-score = 0.5760–0.0017 (95% CI 0.00008183–0.00328055)
HbA1c
3 ln(HbA1c), and DV shunt fraction mean z-score = 0.4529–
0.0017 (95% CI 0.00300435 to 0.00047375) HbA1c3 ln(HbA1C).
[Color figure can be viewed at wileyonlinelibrary.com].
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maternal glycemic control at conception and in early
pregnancy and the relation between HbA1c and DV flow
underlines the effect of the periconceptional environment
on later fetal and neonatal health. This is in line with
other studies where less optimal glycemic control in the
first trimester (HbA1c >6.5 mmolL1) was associated
with accelerated fetal growth (36), and the levels of
biomarkers for placentation and placental growth factor
in the first trimester of PGDM pregnancies had an impact
on birthweight (37).
Growth-restricted fetuses shunt a larger fraction of the
UV blood through the DV (18,19), graded according to
the severity of placental compromise, ranging from 25 to
57% (18). The PGDM fetuses in the present study had a
mean DV shunting of only 18% (Figure 3), mainly
caused by the reduction in DV flow velocity, and in spite
of a distended DV diameter (Appendix S2). It appears
that this blood distribution to the liver is driven by meta-
bolic factors, mainly as reduction of the liver vascular
resistance. This corroborates the finding that the liver vas-
culature is more sensitive to endocrine regulation com-
pared with the DV (31).
The diabetic intrauterine environment can induce
chronic fetal hypoxemia (21,38), but the mechanisms that
protect the fetus during hypoxemia (18) seem less devel-
oped in PGDM fetuses near term. This is supported by
the finding of reduced DV shunt fraction in our study,
and a tendency toward lactacidemia at delivery in those
with low capacity for DV shunting (Figure 3b). Further-
more, this pattern is augmented according to the degree
of glycemic control in the first trimester (Figure 4). The
level of HbA1C influenced the fetal venous circulation,
supporting the clinical focus on tight periconceptional
glucose and dietary control in women with DM.
The strengths of this study are the prospective longitu-
dinal design involving an unselected group of PGDM
pregnancies and identical methods applied to the study
and reference populations. Low intra- and interobserver
variation has been demonstrated earlier for DV flow
velocities (23) and almost identical results for UV flow
were achieved by different investigators using the same
technique for ultrasound measurement and blood flow
calculation (26,39). Measurement success rate was lower
in the PGDM group than in the reference study, probably
explained by the higher BMI in the study population
(24), causing challenging examination conditions
(Table 1). Since the intergroup BMI was higher in the
missing compared with the non-missing PGDM data
group (data not shown), this may have introduced a
selection towards a leaner study population, more similar
to the reference. However, such a selection is expected to
reduce rather than augment the differences between the
study group and the reference population. Technical
challenges related to the angle and depth of insonation
could also introduce systematic errors by underestimating
flow velocities, but in the lower gestational ages the mea-
sured velocities did not differ from the reference popula-
tion. The increasing difference in flow velocity with
gestational age is thus physiologically plausible and sup-
ports the validity of the results.
The objective of the present study was to assess the
fetal circulatory physiology in PGDM pregnancies and the
study was not powered for subgroup analysis related to
the mother (for example diabetic vasculopathy) or the
fetus (intrapartum hypoxia). Nonetheless, the results war-
rant further research in this section of the circulation to
develop clinical tools for identifying PGDM fetuses at
risk.
Epidemiological studies indicate that the increased risk
of adverse outcomes in PGDM, including stillbirth, is
limited to the last weeks of pregnancy (2). Our findings
in these PGDM pregnancies suggest that prioritizing UV
flow to the liver at the expense of DV shunting could
increase fetal vulnerability in late pregnancy and during
labor.
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Appendix S1 
Reference population (1), gestational age (GA) in weeks. 
 
Umbilical vein (UV) diameter, mean and variance 
Mean diameter was transformed to the 0.382 power. 
Transformed mean =  
0.48101595044136+0.0000758466339902953·GA3-0.0000190573191503063·GA3·ln(GA) 
Variance =  
0.00109042716212571-2.56153676048144 E-08·GA3 + 7.80816600612355E-13·GA6 
 
Umbilical vein velocities, mean and variance 
Mean velocity was transformed to the -0.166 power. 
Transformed mean =  
0.64591223+263.12112427·GA-2-90.02454376·ln(GA)·GA-2 
Variance =  
0.00033238372998312 
 
Ductus venosus (DV) diameter, mean and variance 
Mean diameter was transformed to the -0.266 power. 
Transformed mean = µ 
= 2.0811376572-0.0000838075·(GA)3+0.0000209877·ln(GA)·GA3 
Variance =  





Study population, pregnancies with pregestational diabetes, gestational age (GA) in weeks 
 
UV flow volume 
Mean UV flow volume was transformed to the 0.282 power. 
Transformed mean =  
1.162891865+0.00090542360GA3-0.00023297807GA3·ln(GA) 
Variance =  
 0.208563655614853  
 
Normalized UV flow volume, mean and variance 
Mean normalized UV flow volume was transformed to the -0.119 power. 
Transformed mean =  
 0.5998132229-0.000014567·GA3+0.0000041554GA3·ln(GA) 
Variance =  
0.0004220234-0.00000000752759·GA3+0.0000000000001261475·GA6 
 
DV flow volume  
Mean flow volume was transformed to the -0.025 power. 
Transformed mean=  
0.6633474231 + 1.2373400927·GA-0.5 + 0.0000011074·GA3 
Variance =  
 0.000199967034859583 
 
Normalized DV flow volume, mean and variance 
Mean Normalized DV flow volume was transformed to the 0.383 power. 
Transformed mean= 
2.32871628+0.12603378·GA - 0.00349011·GA2 
Variance = σ2 
= 0.45418781 
 
DV shunt fraction  
Mean DV shunt fraction was transformed to the 0.302 power. 
Transformed mean = 
2.1142778+0.000216869GA3-0.000059556598GA3·ln(GA) 
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Pregestational diabetes is associated with fetal macrosomia, and umbilical perfusion of the
fetal liver has a role in regulating fetal growth. We therefore hypothesized that pregestational
diabetes alters fetal liver blood flow depending on degree of glycemic control.
Methods
In a prospective study, 49 women with pregestational diabetes underwent monthly ultra-
sound examinations during 24–36 gestational weeks. Blood flow was determined in the
umbilical vein, ductus venosus and portal vein, and blood velocity was measured in the left
portal vein, the latter reflecting the watershed between splanchnic and umbilical flow. The
measurements were compared with reference values by z-score statistics, and the effect of
HbA1c assessed.
Results
The umbilical venous flow to the liver (z-score 0.36, p = 0.002), total venous liver flow (z-
score 0.51, p 0.001) and left portal vein blood velocity (z-score 0.64, p 0.001), were higher
in the study group. Normalized portal venous flow was lower (z-score -0.42, p = 0.002), and
normalized total venous liver flow tended to be lower after 30 gestational weeks (z-score
-0.54, p = 0.047) in the diabetic pregnancies compared with reference values from a low-risk
population. The left portal vein blood velocity was positively, and the portal fraction of total
venous liver flow negatively correlated with first trimester HbA1C.
Conclusions
In spite of increased umbilical blood distribution to the fetal liver, graded according to glyce-
mic control, the total venous liver flow did not match third trimester fetal growth in pregnan-
cies with pregestational diabetes, thus contributing towards increased perinatal risks and
possibly altered liver function with long-term metabolic consequences.
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Introduction
Pregnancies complicated by pregestational diabetes mellitus (PGDM) are associated with
increased perinatal morbidity and mortality [1], and fetal macrosomia is related to these
adverse neonatal outcomes [2]. Fetal hyperglycemia and hyperinsulinemia can cause acceler-
ated fetal growth [3] even with HbA1C levels within the recommended range [4], and this
makes clinical surveillance in diabetic pregnancies challenging [5].
The liver has been called “the metabolic brain” of the fetus [6], controlling the distribution
and utilization of nutrients from the placenta. Nutrient access and fetal liver blood flow act
both independently and together to influence fetal growth and body composition [7, 8]. The
fetal liver has two sources of venous supply; well-oxygenated blood from the placenta through
the umbilical vein being the main source, and low-oxygenated blood from visceral organs
through the portal vein. The distribution of the nutrient rich umbilical venous blood to the
liver has been suggested to be a mechanism for regulation of fetal growth [9]. This is based on
experimental studies showing that increasing liver flow from the umbilical vein leads to higher
cell proliferation in the liver, heart, skeletal muscle and kidneys in fetal lamb [9]. In addition,
studies of human low-risk pregnancies have shown that larger fetal size is associated with
higher umbilical venous liver flow as a response to maternal glucose intake [10]. Also, higher
umbilical venous flow to the liver is associated with newborn adiposity [11].
In studies of macrosomic fetuses in non-diabetic pregnancies, umbilical- and total venous
liver flow was higher during the 2nd and 3rd trimester, including when normalized for esti-
mated fetal weight [7, 12]. This indicates that increased umbilical venous flow led to aug-
mented fetal growth in pregnancies without diabetes. In low-risk pregnancies, the portal
venous contribution to the liver increases throughout gestation, and the same pattern is
observed in macrosomic non-diabetic fetuses [7]. However, although the fetal liver is larger
[13] and macrosomic growth is frequent in diabetic pregnancies [4], umbilical venous flow
normalized for fetal weight, is lower [13, 14].
Fetal liver gene expression in baboons is different in the left and right liver lobes [15], and
this is ascribed to the specific venous perfusion pattern during fetal life. Thus, fetal hemody-
namic development might influence liver function and be part of a pathway regulating intra-
uterine growth, with possible long-term consequences [7, 12].
In diabetic pregnancies, fetal liver size measured by ultrasound is greater than in low-risk
pregnancies and liver volume positively correlates with maternal HbA1C [13]. Experimental
studies in pigs showed that diabetes induces fetal liver hyperplasia [16], the fetal liver protein
synthesis and glycogen reserves increase [16], and total body fat percentage is higher than in
non-diabetic controls [17]. In human stillborn neonates of diabetic mothers, hepatic steatosis
is prevalent and more severe than in stillborn of non-diabetic pregnancies [18].
Fetuses of women with PGDM have greater risk of later diabetes independently of genetic
factors [19], possibly mediated through epigenetic mechanisms. It has been suggested that the
human fetal strategy to prioritize fat deposition for neonatal survival evolved under conditions
where high glycemic diets were not available; but with their currently widespread consump-
tion, these mechanisms enhance fetal fat deposition [20]. As both diabetes [21] and chronic
liver disease [22] are becoming increasingly prevalent, and there is currently much interest in
the developmental origins of these conditions, studies of factors such as maternal diabetes on
fetal liver development are called for as a basis for informing preventive strategies [23]. We
therefore aimed to determine the fetal liver blood flow in PGDM pregnancies in a prospective
longitudinal study and present the longitudinal development of venous liver blood flow during
the second half of PGDM pregnancies.
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Materials andmethods
The present prospective longitudinal observational study is part of a larger project investigat-
ing fetal hemodynamics in pregnancies with PGDM. The study protocol was approved by the
Regional Committee for Medical and Health Research Ethics (REK vest 2011/2030). We have
reported the development of the umbilical venous and ductus venosus flows in this population
[14]. Here we present data on the development of the venous supply to the fetal liver in PGDM
pregnancies. We have used the left portal vein blood velocity as a marker of the watershed
between the portal and umbilical venous contributions (Fig 1).
Subjects
All women in our region, with PGDM in pregnancy, are referred to our tertiary center at Hau-
keland University Hospital for multidisciplinary follow-up. All women with singleton preg-
nancies and PGDM who presented at our clinic between August 2013 and May 2016 were
invited to participate. Fifty-two women (74% of those invited) gave written consent: 44 partici-
pants had type 1 diabetes mellitus (DM) and 8 had type 2 DM of which all received gestational
insulin treatment. Three participants with type 2 DM withdrew, leaving a total of 49 PGDM
pregnancies for statistical analyzes. Gestational age (GA) was determined using a vaginal
probe (Vivid 7, GE Healthcare Vingmed Ultrasound, E8C, 8 MHz) at the first visit (around
week 9), by measuring the crown rump length [24]. No fetal malformations were revealed by
Fig 1. Venous supply to the fetal liver. Cross section of the fetal abdomen with black arrows indicating physiological
blood flow directions in the fetal liver (grey). Typically, well-oxygenated umbilical blood (red) blends in with
deoxygenated portal blood (blue) to feed the right liver lobe; UV, umbilical vein; DV, ductus venosus; LPV, Left portal
vein; PV, portal vein; S, spine; V, stomach.
https://doi.org/10.1371/journal.pone.0211788.g001
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second-trimester routine scans in the study population. Information on first trimester mater-
nal HbA1C, neonatal sex, birthweight, mode of delivery, Apgar score, cord-blood gases, and
transfer to the neonatal ward was collected from clinical records. The results from the study
group were compared with reference ranges established in the same research unit using identi-
cal methods, in a longitudinal study of 160 low-risk pregnancies [25, 26].
Measurements
The ultrasound examinations were performed in each pregnancy at gestational weeks 24, 28,
32, and 36. All ultrasound measurements were performed by three observers (A.L., J.K. and C.
E.) using an abdominal transducer (M4S, 2.0–4.3 MHz) ultrasound system (Vivid 7, GE
Healthcare Vingmed Ultrasound, Horten, Norway). The sessions lasted maximum one hour
and the thermal index was kept below 1.0.
The time-averaged maximum blood velocity (TAMXV) was measured in the umbilical
vein, ductus venosus, left portal vein and portal vein (Fig 1). The angle of insonation was kept
small, not exceeding 30˚ (median angle correction was 0, range 0–30˚). At the same site per-
pendicular to the vessel wall, the inner vessel diameter (D) was measured at least three times in
the umbilical vein, ductus venosus and portal vein. The mean D was used for the analyses (Fig
1). After identification of the vessel, the color Doppler was turned off and D was measured in
magnified images. The techniques applied are described in detail elsewhere [25, 26].
Blood flow (Q, mLmin–1) was calculated by the formula Q = π  (D/2)2  h  TAMXV. The
velocity profile parameter was h = 0.5 for the umbilical vein (UV) and the portal vein (PV)
[26], h = 0.7 for the ductus venosus (DV) [27, 28]. Flow was normalized based on the estimated
fetal weight (EFW) as Q/EFW (mLmin–1kg–1) [29]. Umbilical venous liver flow (UVliver) was
calculated asQUV liver =QUV −QDV, total liver flow asQliver = (QUV −QDV) +QPV and PV frac-
tion (FPV) of the total venous supply to the liver was FPV = 100%  QPV/Qliver.
Statistics
The sample size was based on our previous studies in non-diabetic pregnancies, demonstrating
significant associations between fetal growth patterns and variation in the venous liver circula-
tion [7, 30]. We allowed for lower measurement success rates and possibly smaller effects in
the PGDM group by increasing the number of participants from 30 to 50. It was not possible
to perform a formal sample size calculation since there were no earlier reports on the effects of
PGDM on fetal liver flow.
Multilevel regression analysis was used to model the mean and standard deviation values
for the outcome variables according to gestational age. The absence of overlap of the 95% con-
fidence intervals of the mean indicated a statistically significant difference between the PGDM
group and the reference values [25, 26, 31]. In addition, z-scores for means of outcome vari-
ables in the study population were compared with the reference group using the independent-
samples t-test, with a significance cutoff of p0.05. The populations were also stratified for ges-
tational age (GA</ 30 weeks), and independent sample t-tests comparing mean z-scores
were performed to test differences between PGDM and low-risk pregnancies before and after
30 weeks of gestation. The relations between maternal first-trimester HbA1c and left portal
vein flow velocity, portal venous flow, and portal venous shunt fraction z-scores after 30 gesta-
tional weeks were assessed using multilevel regression analysis. The statistical analyses were
performed with the Statistical Package for the Social Sciences (version 24, SPSS, Chicago, IL)
and the MLWin program (version 2.35, Centre of Multilevel Modeling, University of Bristol,
UK).
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Results
The characteristics of the study population are described in Tables 1 and 2. The median gesta-
tional age at birth was lower and birthweights were higher in the study group than in the refer-
ence population [31]. In the study group, 19 (39%) of the neonates were macrosomic
(birthweight>90th percentile) and 3 (6%) were small for gestational age (<10th percentile)
[29] (Tables 1 and 2).
The left portal vein and portal vein blood velocity, and the portal vein diameters, were suc-
cessfully measured in 94.4%, 70.9% and 55.9% of 179 examination sessions, respectively. Fur-
ther, portal venous flow was calculated in 52.5%, total venous liver flow (Qliver) in 42.5%, and
the portal venous fraction of the total venous liver flow in 42.5% of the sessions. The success
rate for the umbilical vein and ductus venosus measurements have been published earlier [14].
The mean left portal vein flow velocity in the PGDM group was significantly higher than
the reference values, both before and after 30 weeks (Table 3, Fig 2A).
The mean portal venous flow in the PGDM pregnancies was not significantly different
from the reference values over the study period as a whole, but was significantly higher for the
period before 30 weeks of gestation, and the development after 30 weeks was blunted com-
pared with the reference values (Fig 3A). When normalized for EFW, the overall mean portal
venous flow was significantly smaller in PGDM, mainly due to reduced flow after 30 weeks of
gestation (Table 3 and Fig 3B).
Table 1. Maternal characteristics and outcomes in 49 pregnancies with pregestational diabetes mellitus.
Number Percent
Type 1 DM 44 89.8
Type 2 DM 5 10.2
Maternal diabetic complications or condition
- Retinopathy 9 18.4
- Nephropathy 1 2.0
- Hypothyroidism 9 18.4
- Chronic hypertension 7 14.3
Preeclampsia 3 6.1
Preterm birth 15 30.6
Induction of labor 30 61.2
Normal delivery 20 40.8
Operative vaginal delivery 7 14.3
Cesarean section 22 44.9
- Elective 9 18.4
- Acute 13 26.5
Median Range
Maternal age (years) 31 23 to 42
Pre-pregnancy weight (kg) 70 57 to 113
Maternal weight gain 15.8 -5.0 to 33.1
Pre-pregnancy BMI 24.9 19.8 to 44.1
HbA1c at inclusion (%) 6.7 4.9 to 12.0
Individual mean HbA1c† (%) 6.12 4.9 to 8.2
DM, diabetes mellitus; Preterm birth, gestational age<37 weeks
acute cesarean section during labor
†mean of all HbA1c measurements throughout each pregnancy
https://doi.org/10.1371/journal.pone.0211788.t001
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The total venous supply to the fetal liver (Qliver) was larger in PGDM pregnancies (Table 3),
mainly due to high volumes in the second trimester (Fig 4A). When normalized for EFW, the
overall mean total venous liver flow in the PGDM group did not differ from that of the refer-
ence values but was significantly smaller after 30 weeks and with a different trajectory of the
mean curve (Table 3 and Fig 4B).
In the study group, the mean portal venous fraction for all observations through pregnancy
did not differ from the low-risk group (Table 3). However, the curve describing mean portal
venous fraction had an inverted U-shape in PGDM fetuses, the opposite of that in the refer-
ence group, where the portal venous fraction increased after week 33 (Fig 2B).
The overall mean umbilical venous liver flow (Q UV liver) was higher in PGDM pregnancies
compared with the reference, mainly due to the high flows before 30 weeks of gestation (Fig
5A). However, when normalized for EFW, the overall mean umbilical venous liver flow was
not different from low-risk pregnancies (Table 3), but the trajectory of the flow development
tended to be different in PGDM pregnancies with borderline significantly lower flow after 30
weeks (Table 3, Fig 5B).
The z-scores for left portal vein blood velocity were positively related to first trimester
HbA1C and correspondingly, the z-scores for portal venous fraction were negatively related to
Table 2. Neonatal characteristics and outcomes in pregnancies with pregestational diabetes mellitus.
Median Range
Gestational age at delivery (weeks+days) 38+4 27+6 to 40+5
Birthweight (g) 3695 990 to 5990
Birthweight z-score 0.93 –2.15 to 5.82
Umbilical artery
- pH 7.24 6.92 to 7.34
- pCO2 (kPa) 7.88 5.80 to 12.40
- pO2 (kPa) 2.19 1.16 to 3.47
- Base deficit (mmolL–1) –2.11 –13.36 to 1.00
- Lactate (mmolL–1) 4.70 2.00 to 14.40
Umbilical vein
- pH 7.30 6.89 to 7.44
- pCO2 (kPa) 6.10 4.20 to 15.30
- pO2 (kPa) 3.29 0.25 to 5.68
- Base deficit (mmolL–1) –2.36 –10.98 to –0.15
- Lactate (mmolL–1) 3.50 1.80 to 12.80
Erythrocyte volume fraction 0.63 0.52 to 0.76
Number Percent
Male sex 25 51%
Operative delivery for intrapartum fetal distress 13 26.5%
Metabolic acidosis at birth 1 2%
5-min Apgar score<7 1 2%
Neonatal intensive care 20 40.8%
Perinatal death† 1 2%
Malformation‡ 2 4%
 Metabolic acidosis defined as an umbilical arterial pH of<7.0 and a base deficit of>12.
† Intrauterine fetal death at gestational week 36. Autopsy showed UV thrombosis and signs of acute asphyxia.
‡ One neonate with sagittal craniosynostosis and one with congenital heart defect (anomalous left coronary artery
from the pulmonary artery)
https://doi.org/10.1371/journal.pone.0211788.t002
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first trimester HbA1C (Fig 6). There was no relation between HbA1C and portal venous or total
venous liver flow.
Since 39% of the neonates in our PGDM group were macrosomic, we compared the devel-
opment of the total venous liver, umbilical and portal flows in low-risk, non-diabetic macroso-
mic and PGDM pregnancies, to illustrate the different flow patterns (Fig 7).
We compared the mean z-scores in the T1DM group with the reference values for LPV
velocity, PV flow, normalized PV flow, total venous liver flow, normalized venous liver flow
and UV liver flow (S1 Table). Excluding T2DM participants from the PGDM population did
not significantly change the results, except for PV flow which then became borderline signifi-
cantly higher compared with the reference values (p = 0.046).
Table 3. Fetal venous liver blood flow in pregnancies complicated by pregestational diabetes mellitus compared with reference values from a low risk population.
Parameter Popu-lation n Mean z-score p GA <30 Mean z-score GA<30p GA30 Mean z-score GA30p
(95% CI) (95% CI) (95% CI)
LPV velocity (cm/s) Ref. 537 0.003 <0.001 0.011 <0.001 -0.005 <0.001
(-0.09–0.09) (-0.11–0.13) (-0.12–0.12)
PGDM 201 0.639 0.675 0.575
(0.49–0.79) (0.46–0.89) (0.29–0.86)
PV flow (mLmin–1) Ref. 547 0.011 0.052 0.016 0.005 0.006 0.131
(-0.09–0.11) (-0.10–0.13) (-0.12–0.13)
PGDM 93 0.272 0.796 -0.466
(0.03–0.52) (0.26–1.32) (-1.07–0.14)
Normalized PV flow (mLmin-1kg-1) Ref. 547 0.007 0.002 0.022) 0.821 0.009 0.002
(-0.10–0.11) (-0.09–0.13 (-0.14–0.12)
PGDM 93 -0.418 0.089 -1.132
(-0.67 - -0.17) (-0.49–0.67) (-1.80 - -0.46)
Total venous liver flow, Qliver (mLmin–1) Ref. 514 -0.005 <0.001 -0.008) 0.001 -0.001 0.881
(-0.10–0.09) (-0.13–0.11 (-0.13–0.13)
PGDM 75 0.507 0.847 -0.045
(0.26–0.75) (0.39–1.30) (-0.63–0.54)
Normalizedvenous liver flow (mLmin–1kg–1) Ref. 473 0.010 0.479 0.007 0.342 0.033 0.047
(-0.09–0.11) (-0.13–0.11) (-0.11–0.17)
PGDM 75 -0.085 0.195 -0.538
(-0.33–0.16) (-0.21–0.60) (-1.08–0.01)
PV fraction of total venous liver flow (%) Ref. 511 0.004 0.645 -0.002 0.909 0.012 0.550
(-0.09–0.10) (-0.12–0.11) (-0.12–0.14)
PGDM 75 -0.098 0.028 0.217
(-0.35–0.16) (-0.49–0.54) (-0.46–0.89)
UV liver flow, QUV liver (mLmin–1) Ref. 558 0.00 0.002 -0.02 <0.001 0.01) 0.952
(-0.09–0.10) (-0.13–0.09) (-0.11–0.14
PGDM 122 0.364 0.65 0.00
(0.16–0.57) (0.23–1.06) (-0.37–0.38)
Normalized UV liver flow (mLmin–1kg–1) Ref. 558 0.004 0.229 -0.05 0.630 0.03) 0.049
(-0.09 –-0.10) (-0.17–0.07) (-0.09–0.15
PGDM 122 -0.131 0.03 -0.33
(-0.33–0.06) (-0.35–0.41) (-0.67–0.00)
PGDM, pregestational diabetes mellitus; Ref., low-risk reference group [25, 26]; n, number of observations; CI, confidence interval for the mean z-score; p, probability
value; GA, gestational age (weeks)—before and after 30 weeks; LPV, Left portal vein; PV, portal vein; Qliver, total venous liver flow; PV fraction (%) = (PV flow/Total
liver flow)100; Q UV liver, umbilical venous flow to the liver
https://doi.org/10.1371/journal.pone.0211788.t003
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Fig 2. Longitudinal observations of left portal vein blood velocity and portal venous fraction in PGDM and low-risk pregnancies. Left portal vein blood velocity
(TAMXV) as marker of the watershed between portal and umbilical contribution to fetal venous liver flow (a), and the portal fraction (%) of total venous volume (b) in
49 pregnancies with pregestational diabetes (PGDM; red circles and lines) compared with reference values from a low-risk population (black lines) presented with mean
(thick lines) and 95% confidence interval (thin lines).
https://doi.org/10.1371/journal.pone.0211788.g002
Fig 3. Longitudinal observations of portal venous flow in PGDM and low-risk pregnancies. Portal venous flow (a) and normalized portal venous flow (b) in 49
pregnancies with pregestational diabetes (PGDM; red circles and lines) compared with reference values from a low-risk population (black lines), with mean (thick lines)
and 95% confidence-interval (thin lines).
https://doi.org/10.1371/journal.pone.0211788.g003
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Discussion
In pregnancies complicated with PGDM, the fetal liver perfusion with nutritious umbilical
blood from the placenta was prioritized (Table 3, Figs 1 and 2A). This effect was graded
according to the maternal HbA1c level (Fig 6) and was associated with correspondingly accel-
erated fetal growth during the 2nd trimester. However, the blunted umbilical flow development
Fig 4. Longitudinal observations of total venous supply to the fetal liver in PGDM and low-risk pregnancies. Total venous liver flow (a) and the
correspondingly normalized flow values (b) in 49 pregnancies with pregestational diabetes mellitus (PGDM; red circles and lines) compared with reference
values from a low-risk population (black lines) presented with mean (thick lines) and 95% confidence interval (thin lines).
https://doi.org/10.1371/journal.pone.0211788.g004
Fig 5. Longitudinal observations of the umbilical venous supply to the fetal liver in PGDM and low-risk pregnancies.Umbilical venous liver flow (a) and
the correspondingly normalized flow values (b) in 49 pregnancies with pregestational diabetes mellitus (PGDM; red circles and lines) compared with reference
values from a low-risk population (black lines) presented with mean (thick lines) and 95% confidence interval (thin lines).
https://doi.org/10.1371/journal.pone.0211788.g005
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during the 3rd trimester seemed to cause an increasing mismatch between growth and blood
supply (Table 3, Figs 2–5).
The venous supply to the liver is radically different in fetal and postnatal life, with contribu-
tions from both the umbilical (80%) and the portal vein (20%) (Figs 1 and 7) [26]. Thus,
the umbilical vein is the principal source of fetal liver blood supply [31], and this umbilical
venous flow to the liver is augmented in diabetic pregnancies (Table 3, Fig 5A). Such increased
delivery of oxygen and nutrient rich umbilical venous blood to the liver, is thought to be
instrumental in the development of macrosomia [8].
The left portal vein connects the umbilical vein with the portal circulation and directs
umbilical venous blood to the right lobe of the liver (Fig 1). Blood flow in the left portal vein is
regulated by catecholamines [32] and maternal glucose levels [10]. Measurement of the left
portal vein velocity alone provides a simple method for gauging the umbilical/portal watershed
and for assessment of intrahepatic venous redistribution in compromised fetuses [25]. In the
present study, the mean left portal vein velocity was higher in PGDM pregnancies than the ref-
erence values, throughout the second half of pregnancy (Fig 2A). This signifies increased prior-
itization of umbilical blood flow to the right liver lobe and is known to induce liver growth,
increased production of IGF-1 and -2 and in turn, differential organ growth [8, 9].
The portal contribution to the venous liver perfusion was higher in PGDM than the refer-
ence group before 30 weeks (Table 3), but the portal venous flow did not keep up with fetal
Fig 6. Fetal liver blood flow and relation to HbA1C. Relations between z-scores of the time-averaged maximum left portal vein (LPV)
flow velocity (TAMXV) and portal vein (PV) fraction, and first-trimester HbA1c.
https://doi.org/10.1371/journal.pone.0211788.g006
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growth later in pregnancy (Fig 3B). This corroborates a study of Olofsson et al., showing that
blood flow to the lower extremities was prioritized at the expense of visceral blood flow during
the third trimester, in pregnancies with type 1 DM [33]. In addition, lower portal venous
return could be a result of reduced fetal swallowing or intestinal activity in diabetic pregnan-
cies [34]. We hypothesize that the increased umbilical venous flow to the right liver lobe
observed in our study, may induce accelerated fetal growth that is less supported by umbilical
venous supply at the end of pregnancy, and without any increase of portal blood flow to the
liver. Higher umbilical venous flow to the right liver lobe, as found in our study, could also
influence liver gene expression [15], fetal body composition [11] and possibly later health [20].
In the present study, 39% of the newborns had a birthweight> 90th percentile for gesta-
tional age (Table 2). Fetal macrosomia in PGDM is different from that in non-diabetic preg-
nancies, with disproportionate fetal growth expressed as a higher ponderal index [35]. In a
study of macrosomic fetuses withoutmaternal diabetes, the umbilical venous perfusion [12],
left portal venous flow, portal and total venous liver flow, were all increased during the second
half of pregnancy [7], even when corrected for fetal weight. Similarly, in the present study,
high umbilical venous flow [14], correspondingly low placental impedance [36] and increased
portal blood flow permit an up-regulation of liver flow before 30 gestational weeks (Table 3,
Figs 2–5). In contrast, after 30 weeks gestation, fetuses of diabetic mothers had reduced portal
and total venous liver flow when normalized for fetal weight, while in non-diabetic macroso-
mic fetuses no restriction in venous blood flow to the liver was observed (Table 3, Fig 7).
It is known that during placental compromise associated with fetal growth restriction,
shunting through the ductus venosus is prioritized at the expense of the umbilical venous liver
flow [37, 38]. This leads to reduced liver size that increasingly depends on the low-oxygenated
portal flow. In PGDM pregnancies however, the increased risk of chronic hypoxemia, acidosis,
and perinatal death in the last weeks of gestation [39–41] follows relatively greater umbilical
supply during the 2nd trimester (Table 3). The liver received umbilical blood at the expense of
flow through the ductus venosus [14]. Towards the end of pregnancy, PGDM fetuses outgrew
their supply of umbilical venous blood and did not maintain portal flow corresponding to
Fig 7. Fetal venous liver flow development in pregnancies with low risk, macrosomia and PGDM. The fetal venous liver
flow in three different populations: a low-risk population (physiological venous liver flow during the last weeks of pregnancy;
dotted lines), fetal macrosomic growth withoutmaternal diabetes, and pregnancies with pregestational diabetes mellitus
(PGDM, the present study population).
https://doi.org/10.1371/journal.pone.0211788.g007
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their weight (Figs 2 and 3). Although being at risk of relative hypoxia, the re-distribution
mechanisms well-known in fetal growth restriction did not seem to operate.
The strengths of this study are its prospective longitudinal design, involving an unselected
group of PGDM pregnancies, and identical and validated ultrasound and Doppler methods
applied to the reference population [42]. Low intra- and inter-observer variation has been
demonstrated for measurements of ductus venosus flow velocities [43], and almost identical
results for umbilical venous flow were achieved by different investigators using the same tech-
nique for ultrasound measurement and blood flow calculation [26, 44, 45]. The success rate for
measurements varied from 93.4% for left portal vein blood velocity to 52.5% for portal venous
flow, the latter being lower than in the reference population [26]. This was mainly due to diffi-
cult examination conditions caused by high BMI in our study group. Although there was no
inter-group difference in liver flow between PGDM participants with BMI< or30, a selec-
tion bias cannot entirely be ruled out. Because the BMI was borderline significantly higher in
the missing compared with the complete data group (tested by independent sample t-test,
mean BMI z-score in the QUV liver missing data vs. non-missing data groups were 1.47 and
1.13 respectively, p = 0.07) this could introduce selection of a leaner PGDM population for the
estimation of umbilical venous liver flow. However, such a selection is expected to reduce
rather than augment the differences between the study- and the reference populations. Also,
wider confidence intervals in the study group compared with the reference group warrant a
cautious interpretation of the findings.
Including women with type 1 and type 2 DM in one study group may represent a limita-
tion, since these conditions differ in many respects. Our goal was however, to study fetal flow
and growth in pregnancies with PGDM. Our population was not large enough to answer the
question of whether fetal venous liver circulation is different in pregnancies with type 1 or type
2 DM. Nevertheless, when women with type 2 DM were excluded the findings remained sig-
nificant in the type 1 DM group (S1 Table).
Conclusion
Maternal diabetes is associated with adverse consequences in the offspring [46], including
macrosomia and metabolic syndrome [47], but the underlying mechanisms are not estab-
lished. Fetal liver blood flow is linked to fetal growth, and we showed that flow is related to
maternal blood glucose in the first trimester in PGDM pregnancies. However, the relatively
greater liver perfusion in PGDM pregnancies before 30 weeks was not maintained in late ges-
tation, possibly leading to mismatch between fetal growth and nutrient supply, and later effects
on health.
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Supporting information 
S1 Table 
Fetal venous liver blood flow in pregnancies complicated by type 1 diabetes mellitus 
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Ref., low-risk reference group ; n, number of observations; CI, confidence interval for the 
mean z-score; p, probability value; LPV, Left portal vein; PV, portal vein; Qliver, total venous 
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